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ABSTRACT
ESTABLISHING COMMUNITY AND RESEARCH TRUST IN PUBLIC HEALTH
USING SERVICE-ORIENTED ARCHITECTURE (SOA)
by Juanita H. Mah

One of the major challenges of community-based research is recruitment of community
members who will participate in clinical trials, continue for the duration of the trial, and
provide accurate sensitive personal information. This challenge can be overcome by
establishing greater trust between researchers and communities.

This study focuses on a system to address trust issues between the San Jose Hispanic
community and clinical researchers. It describes a methodology for translating nonfunctional wants and needs into technical requirements that are used as input to a ServiceOriented Architecture (SOA) approach to design a solution. Unlike a typical SOA that is
derived from a single enterprise’s business goals and processes, this solution is based on
multiple stakeholder goals and general clinical trial processes.

The resulting architecture focuses on improving communication between researchers and
communities and is validated by mapping the technical requirements against a trustbuilding model and modeling the solution using Petri nets.
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I Introduction

Clinical researchers use clinical trials to evaluate the effectiveness and safety of
medications or medical devices by monitoring their effects on large groups of people [1].
Clinical trials may be used to test new approaches for preventing, detecting, diagnosing,
or treating disease and are concerned with issues such as drug safety, appropriate dosages
and dose administration, efficacy, and treatment side effects [2].

Clinical trials may be sponsored by a variety of public and private concerns, such as
government health agencies, hospital or university researchers, independent researchers,
pharmaceutical companies, or biomedical device companies. Plans for a clinical trial
must first be approved by the federal government. After approval, trial execution and
results are monitored by government agencies. Typically, these agencies approve or
disapprove new treatments based on the results of the trial [1], [2], [3].

A study may include multiple clinical trial phases. Each phase has its own purpose; and
the number of participants increases with each subsequent phase. The duration of a phase
varies. Typically, the earlier phases last one to two years, while the later phases are
longer and can last 5 years or more [3].

Clinical trials can involve patients as well as healthy individuals. In most cases, these
research subjects are volunteers; but sometimes they might be paid. Each candidate must
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meet certain criteria in order to be eligible to participate in a study. In addition,
researchers must ensure that all candidates are aware of the benefits and risks associated
with participating in the trial prior to enrolling in the trial. The process of ensuring that
participants know key facts about the trial is known as informed consent. The intent of
informed consent is to ensure that the rights and welfare of human subjects are protected
[2], [3].

One of the major challenges of clinical research is the recruitment and retention of
participants in clinical trials. Enough qualified candidates must be enrolled to ensure a
valid sample size. Participants must be fully informed of the potential risks as well as the
benefits of participating. The program must be designed to effectively and accurately
elicit potentially sensitive personal information. Moreover, the program must be
executed in a manner that ensures continued participation by trial subjects for the
duration of the trial. Ineffective recruitment and retention practices can elongate trial
phases and increase treatment development costs.

One way to facilitate recruitment and retention is by taking actions to establish greater
trust between researchers and a community. These actions can be incorporated into each
major stage of a clinical trial phase. For example, during the planning stage, the
informed consent process might be customized to meet the needs of a community.
During the execution stage, actions might be taken to improve communication and
information flow among those directly and indirectly involved. Later, after a trial is
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completed, steps might be taken to inform participants of the results and to collaborate
with them in planning the next trial phase.

A. Thesis Goals.
This thesis focuses on a software solution to address trust-building issues between
clinical researchers and a community where clinical trials are being conducted. A
community is “an association of people who gather together to share a common interest
and/or relevancy during a period of time” [4]. A community may be based on common
points of reference, such as geography, ethnicity, religion, culture, interests, or
organization. This thesis specifically uses the San Jose Hispanic community as the basis
for a case study to determine solution requirements and evaluate the results of the study.

The primary goal of this thesis is to demonstrate how various modeling techniques can be
used to architect a flexible software solution that addresses a shared need between diverse
stakeholders with different but related goals. The output of the study will be a software
system architecture that is intended to improve communication between the researchers
and members of the community. By establishing structured communications among
clinical trial participants, clinical researchers should expect greater trust and
collaboration, thereby increasing participation rates, yielding more valid data input, and
facilitating subsequent research activities.
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First, a methodology will be developed to derive a set of technical requirements for that
system from non-functional wants and needs. Next, to ensure strong linkage and
traceability between the business goals of clinical trial participants and the software
solution, the architecture will be developed using a Services-Oriented Architecture
(SOA) approach. The architecture definition will be in the form of a Service Model,
Goal-Service Model, and Design Model. Last, selected service components will be
modeled using Petri nets as part of solution validation.

B. Expected Contributions to the Body of Knowledge.
This study proposes a methodology for transforming non-functional domain-specific
wants and needs, such as trust building, into technical requirements that can be
implemented via a software system. This methodology will be generalized so it can be
applied to other non-functional problem sets.

Currently, an SOA focuses on a single enterprise’s information technology needs and
strives to establish traceability from that enterprise’s vision and business goals to
individual services to be developed or called by the enterprise solution. This study
extends existing SOA approaches in two ways. First, this study will demonstrate how an
SOA approach can be used to define an architectural solution for a general problem
domain, i.e., the clinical trials process, rather than for a specific enterprise. Second, this
study will show how to define an SOA to achieve common goals of multiple
stakeholders, with traceability back to their respective visions and goals. Last, this study
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explores the use of Petri nets to model web services. Petri nets will be used to model
individual services and relationships among web services within an SOA. Petri net
simulations can be used to validate the architecture’s correctness. These models can also
be used to identify potential implementation issues such as deadlocks and concurrency.

C. Organization of This Thesis.
The remainder of this paper is organized into three parts: The first part contains four
sections and provides background information. In Section II, some of the current
challenges associated with establishing trust between clinical researchers and
communities as well as recommended solutions will be described. Section III examines
specific health and trust issues associated with the San Jose Hispanic community and
introduces a case study. Section IV focuses on the current state of the art and identifies
some existing software that is used by clinical researchers to design and manage clinical
trials. Section V is a brief overview of SOA and its benefits. It also contains a
description of Service-Oriented Modeling and Architecture (SOMA), an approach for
modeling an SOA.

The second part consists of two sections where a proposed software solution will be
derived. In Section VI, a methodology for translating non-functional wants and needs
into technical requirements that can be implemented will be demonstrated. Specifically,
the challenges and solutions identified in Section II will be mapped into requirements for
a software solution. These requirements will be used in Section VII, where an SOA-
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based solution using SOMA will be described. The third and last part contains two
sections in conclusion. Section VIII contains an evaluation of the solution against the
requirements of major stakeholders involved in the clinical trials process; and Section IX
concludes with final thoughts.
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II Trust-Building in Clinical Research

A. Challenges.
According to Getz and Kremidas [5], the state of public relations in the clinical trials
industry declined during the 5-year period of 1999 to 2004 due to the significant lack of
education among the general public, prospective volunteer communities, medical and
health professionals, and media. The authors noted that most communications between
clinical researchers and journalists focused on negative aspects of clinical trial execution
or results.

A survey of nearly 6000 adults [5] showed that 69% of them were aware of clinical trials
through various media and that one in seven were exposed to information through their
primary care or specialty care physicians. However, less than 5% knew where to find
information about relevant clinical trials. A report of approximately 700,000 medical and
health professionals active in community practices showed that less than half of them had
referred a patient to a clinical trial, averaging to less than one patient referral per
practitioner per year.

Moreover, there was significant public distrust in clinical research, especially among
adults in minority communities. Surveys conducted in 1996, 2002, and 2006 [5] showed
a decline of public trust in clinical research information from pharmaceutical companies.
In 1996, 72% of those surveyed trusted clinical research information. By 2006, this
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percentage dropped to only 21%.

Other studies in 2004 and 2006 showed public belief in the effectiveness of the FDA to
ensure consumer safety had declined from 56% to 37% [6]. In a 2004 survey of more
than 5,800 adults, 84% of the Latino respondents gave a response of “not very safe/not
safe at all” to the question, “How safe do you think clinical research studies are for
people who participate [5]?”

Because of these types of issues, 90% of all clinical trials had to extend their timelines in
order to enroll sufficient numbers of volunteers in a study. To complete a trial, research
sponsors had to spend increasingly more resources on patient recruitment, thus increasing
trial costs.

Research that is community-based brings additional challenges to trust-building, due to
its collaborative nature and its need to understand and accommodate the language and
culture of the community. Trust must be established between outside researchers and key
participants within the community, including community leaders, community-based
partners, prospective study subjects, and healthcare providers. Successful healthcare
research involving socio-economically disadvantaged communities depends on the
degree to which that research is “culturally appropriate and relevant to families in the
communities where they live” [7].

8

To establish successful trusting relationships with medical and healthcare professionals
focused on the health of specific communities, a number of barriers must be overcome.
Sometimes researchers may be perceived as outsiders who take data and define research
priorities but do not give back to the community; or they may be perceived as drains to
local resources. In some cases, community members may be intimidated by the technical
training of outside researchers; or they may be suspicious of the researchers’ motives. If
researchers only commit to a short-term partnership, it may be difficult to maintain trust
[4], [7], [8].

There are also many potential barriers to establishing trust with prospective study
subjects in these communities. This includes lack of understanding of the clinical trials
process, lack of informed consent, lack of researcher sensitivity to individual needs, loss
of control by the subject, skepticism about the quality of care received, or opinions of
trusted influencers. When the research process is not thoroughly understood, subjects
may not understand the difference between research and medical care. Therefore, they
may have unrealistic expectations of study participation. They may also fear loss of
medical records privacy. Language and literacy issues may inhibit understanding of the
research process or make informed consent more difficult, so prospective subjects may
not fully understand the benefits and risks of participating in a study. Subjects may feel a
loss of control if they are not provided interim information about a study’s progress.
They may be skeptical of the quality of care they will receive, due to different values and
beliefs. Furthermore, depending on the community culture, a potential subject’s trust
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may be dependent on the views of family, friends, community leaders, and his or her
healthcare providers [4], [7], [9].

Previous experiences in clinical trials can erode trust. Potential subjects may have a
sense of being over-researched but not helped. Lack of follow-up by researchers from
previous trials, lack of follow-through on various commitments, or awareness of
historical mistreatment may significantly impact levels of trust. A subject who
participated in previous studies but did not see any benefits as a result of them is less
likely to trust the clinical trials process. If researchers do not conduct appropriate followup during a trial or communicate study results, participants may become suspicious and
less trustful [7], [8].

As mentioned earlier, physicians and other healthcare providers can play a significant
role in lowering trust barriers and influencing their patients’ decisions to participate in
clinical trials. Some of the reasons for the low rate of referrals by physicians are lack of
awareness or understanding of the clinical trials process, fear of loss of patient control,
and concerns about the resource or time demands associated with trial participation.
Healthcare providers may not understand the importance of clinical research or the
potential benefits and risks associated with participation. If they do not have access to
their patient’s study data, they may not feel sufficiently informed to continue to
adequately treat their patients; or they may fear they will lose their patients after the study
is completed. They may also be reluctant to take on additional administrative work; or
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they may have competing demands for their time [4], [6], [9].

List and Sempeera [7] also include an observation about the lingering effects from prior
participation in community-based research. If a community had a negative experience
from a previous study, it was less likely to participate in another study, even if the two
studies were completely unrelated. This means that inconsistency in approach from study
to study may impact levels of participation in future studies.

When there is lack of trust between clinical researchers and local communities,
researchers may not be able to enroll a sufficient number of active participants into a
clinical trial, those who do enroll may not continue to participate for the duration of the
study, or the data provided by trial subjects may not be complete or truthful. For a
clinical trial to be successful in traditionally underserved communities researchers must
collaborate with the community to address local problems in a meaningful and impactful
way; and trust-building must be incorporated throughout the clinical trials process.

B. Solutions: An Industry Perspective.
The clinical trials process can be divided into planning, execution, and outcome stages.
Actions to build and maintain trust can be incorporated into each of these stages, focusing
on the specific needs of different types of community members, such as communitybased partners, community leaders, prospective trial subjects, and trial subject influencers
such as their healthcare providers, friends, and family. In addition, broad actions can be

11

taken, independent of any particular clinical trial, to increase understanding and literacy
of the clinical trials process among the general public. More details about these actions
are described in following sections.

1) Trial Planning Actions: During the research planning stage, researchers should
involve the entire community in discussions on the local needs, issues, and concerns to
ensure that the study is relevant and will be supported by the community.

These needs

should be used to establish research priorities [6], [7], [8]. Community members should
also be engaged to act as research consumer advocates and be given the opportunity to
contribute to trial design and to ensure that the patient perspective is incorporated into the
process [6].

Researchers should work with community members to design the trial with culturally
appropriate questions, translations, and interactions [7]. This includes collaborating with
partners and leaders to ensure informed consent [6], [7].

Informed consent, a key interaction required in clinical research, is a procedure to ensure
that trial subjects understand the nature of the proposed treatment, possible alternatives,
and potential risks and benefits. Informed consent is a major issue in patient recruitment
and retention; and it is even more important in community-based research, as it can be a
way to empower participants in the decision-making process, thus engendering greater
trust. Eliciting input from community members during the research planning stage can
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make the informed consent process more effective.

To promote greater understanding and awareness of the clinical trials process, research
consumer advocates should be engaged to educate prospective trial subjects about clinical
trials. These research consumer advocates would include community-based partners,
leaders, and influencers. In addition, community physicians and other healthcare
providers should be engaged to talk to their patients about relevant trials and to identify
and refer eligible patients. Community members who had participated in earlier phases
of the clinical trial or who were, themselves, in the pool of eligible trial candidates could
be trained to act as influencers to encourage trial participation [5], [6], [7].

To encourage greater power sharing and control, community members should be included
on the research boards. This would give community representatives more say in how
funds are distributed [6], [7], [8]. Other ways to share power and control might be to
recruit community partners and physicians as study investigators or to utilize their
facilities as part of the study [6].

2) Trial Execution Actions: During the trial execution stage, trust can be maintained by
continuing to share power and control with the community. This should include
community members as research consumer advocates who participate in trial monitoring.
Other activities might include participating on data safety monitoring boards or gathering,
analyzing, and disseminating trial information [6], [8].
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Another way to empower the community would be to ensure frequent communication
between researchers and the community. Primary and secondary physicians should
continue to be informed of their patients’ progress during the trial. Establishing two-way
communication between physicians and researchers could eliminate feelings physicians
might have of loss of control over their patients. Trial participants should also be
continually informed of progress, status, and trial results so they can make informed
decisions about their continued participation. Participants should have a way to
communicate concerns or ask questions; and researchers should be responsive. Ongoing
communication to the community-at-large during the trial would demonstrate concern for
the community [6], [7].

Other ways to demonstrate concern for the community would be to provide health
education to trial subjects, to continue use of culturally appropriate questions and
translations, and to be sensitive to cultural values and beliefs when interacting with trial
subjects [7]. It is also critical that all commitments made by researchers to individuals
are met.

Trust between researchers and candidate trial subjects can be enhanced by using trusted
research consumer advocates and community healthcare providers as intermediaries for
trial recruitment [6], [7]. Trial execution processes should facilitate trial referrals from
these advocates.
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3) Trial Outcome Actions: When a trial is complete, researchers should work with
community-based partners and leaders to determine the most effective ways to
disseminate trial results to trial subjects and influencers to maintain trust [1].

4) General Awareness Actions: The Parkinson’s Disease Foundation (PDF) [6] suggests
addressing the trust issue through greater public disclosure and transparency. The goal
would be to raise awareness of ongoing research and to improve clinical trials literacy.
Pre-education could be used to counter the way the public was receiving information
about clinical research.

To this end, the foundation developed a public web site [10] with extensive information
about current clinical studies. The purpose was to integrate various study registries and
to provide a one-stop shop for people with Parkinson’s Disease (PD). Potential
participants could view information about relevant research and requirements for
participation, testimonials from other participants, and targeted Frequently Asked
Questions (FAQs). Although the web site met the requirement for public disclosure, it
was not producing the desired result. Because of this, PDF recommended additional
actions to increase awareness of and education on clinical research through ongoing oneon-one and community communications [6].

Getz and Kremidas [5] suggest that outreach and advocacy programs are an effective way
to address education and trust issues. Earlier programs were limited in scope and
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duration, resulting in inconsistent messages or only short-term benefits. Because of this,
the authors suggest that these programs be more broadly adopted and implemented across
the entire clinical research professional community and integrated with all clinical
research activities. The authors specifically recommend implementation of these types of
communications: 1) educational materials for potential volunteers that address unique
needs of each community; 2) broad outreach and advocacy to emphasize the important
role of healthcare professionals in the clinical trial process and to educate the general
public about the clinical trials process; 3) generation of messages that convey the
important role that clinical research plays in improving public health and why it is so
costly; and 4) acknowledgement and appreciation for community participation in clinical
trials. Targeted audiences would include the general public, health professionals, policy
makers, prospective trial subjects and their friends and families, and the media.

The proposed actions described above are consistent with the National Institute of
Health’s (NIH’s) Roadmap for Medical Research [4], [11]. This roadmap provides
funding mechanisms to assist communities in developing their own projects. It includes
seven major recommendations for improving trust between researchers and the
community [4]:
•

Recommendation 1: Establish grant criteria.

•

Recommendation 2: Enhance network and infrastructure by funding mechanisms
for grass-roots studies and providing linkages to community groups.

•

Recommendation 3: Integrate medical research into primary healthcare.
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•

Recommendations 4 and 5: Require certain criteria in study design.

•

Recommendation 6: Provide access to information about clinical trials.

•

Recommendation 7: Provide software to determine if a person meets clinical trial
criteria.

These NIH recommendations are consistent with those previously stated and can be used
as additional input into the requirements for a software solution. Establishing a common
approach in the clinical trials process, common study design criteria, and software to
support compliance to processes may improve consistency among various researchers
conducting trials within a community. Consequently, a community’s overall view of
researchers and clinical trials may improve.

C. Solutions: A Community Perspective.
The solutions identified above do not take into account the possibility that there may be
several clinical trials being conducted in a community during the same time period.
When there are multiple clinical trials focused on the same community but sponsored by
different researchers, additional trust-building actions may be required. For example, if
the clinical trials process is inconsistent from sponsor to sponsor or if trials focused on
the similar problems are offering different treatments, trial subject candidates may find it
more difficult to determine which trials to participate in, if they choose to participate at
all.
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Providing a consistent approach across all clinical trials activity targeted at a community
by adhering to the NIH recommendations can reduce inconsistencies and reinforce trust
developed by previous researchers or other concurrent researchers. Working through a
single interface to a community, such as a community-based research organization, can
shield prospective trial subjects from significant differences. These community
organizations can also serve as objective trusted advisors to guide community members
to the most relevant trials.
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III Health in the San Jose Hispanic Community

According to the National Alliance for Hispanic Health, obstacles to providing quality
healthcare “…involve cultural misunderstandings and miscommunications with patient
populations whose languages, experiences, and backgrounds differ from those of their
providers” [12]. This section summarizes primary health issues in the Hispanic
community and explores some cultural characteristics of the San Jose Hispanic
community that may affect their trust in clinical researchers that are focused on these
issues. Next, a case study will be introduced that will be used to guide and evaluate the
solution developed in Section VI and Section VII.

A. Community Health Issues.
Pfizer conducted a study on health data of specific populations in the United States [13],
including Mexican-Americans, and published the results in 2004. Because MexicanAmericans were the largest subgroup of the San Jose Hispanic community (more than
87% during the years 2006 to 2008), the results of the study are pertinent and
summarized here [14].

Health data on high blood pressure, cholesterol, diabetes, and obesity from 1998 to 2000
were analyzed. Mexican-Americans were less likely than non-Hispanic whites to have
high blood pressure or high cholesterol. However, they were more likely to have diabetes
or be obese.
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The data studied shows that the number of Mexican-Americans afflicted with high blood
pressure grew during the study period. In comparison to non-Hispanic whites, the study
found that Mexican-Americans were less likely to be diagnosed and treated. Of those
receiving treatment, Mexican-Americans were less successful in their efforts to lower
their blood pressure to recommended levels. Mexican-Americans were also less likely to
be screened, diagnosed, or treated for high cholesterol. However, if treated, they were
more successful in lowering their cholesterol to recommended levels.

The report shows that diabetes is more common among Mexican-Americans. MexicanAmerican women had nearly twice the rate of diabetes than non-Hispanic white women.
Mexican-American women were also more aware of diabetes; and a larger percentage of
them received treatment.

These three diseases are related to a person’s weight; and the study shows that 33% of
Mexican-Americans were considered obese, with middle-aged Mexican-Americans
having the highest rate at 38% [13]. Obesity may be due to food selection that is based
on cultural preferences, so it is important to understand that culture when developing
recommendations for treatment [14].

B. Cultural Issues Affecting Healthcare.
According to a survey conducted by the American Community Survey in 2008 [14], the
San Jose Hispanic community comprised 31.5% of the population in San Jose, California,
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of over 900,000. Of the city’s population who were 5 years or older, 23.7% spoke
Spanish at home and 11.6% felt they did not speak English well. These significant
percentages indicate that the language issues affecting trust, as described in Section II,
must be considered when planning trust-building actions.

In addition to language, the National Alliance for Hispanic Health [12] identifies three
common cultural characteristics that can influence trust. They include the importance of
family, the need to show respect, and the value of personal relationships. Hispanics
frequently consult with other family members about their illnesses and are more likely to
involve their family members in discussions and decisions about treatments. It is also not
unusual for family members to be asked to accompany a patient during medical visits so
they can be involved in the discussions with the healthcare provider.

In the Hispanic community, respect is demonstrated through “appropriate deferential
behavior towards others based on age, sex, social position, economic status, and
authority” [12]. Because of their status, education, and training, Hispanics tend to value
the opinions and recommendations of their healthcare providers. To avoid being
disrespectful, Hispanic patients might not verbally disagree with their providers or
express doubts.

They also expect that their healthcare providers will show them respect in return. This
respect is demonstrated by the way the healthcare provider interacts with a patient. For
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example, asking direct questions about personal problems such as alcoholism or mental
health can be embarrassing and might be perceived as being disrespectful. Respect is
also shown by listening carefully to patient concerns and responding to them [12].

Hispanics value personal relationships over institutional ones, so they rely on
community-based organizations or clinics for their primary care. They also display
loyalty to their individual providers. If a patient’s physician moves to a different
healthcare facility, it is not unusual for that patient to move to the new facility to keep the
same provider. If a move is not possible, the patient might discontinue treatment
completely.

C. Case Study.
Because obesity is a significant health issue in the Hispanic community, it will be the
focus of the case study. This is a hypothetical study based on an actual study conducted
by Stanford University in 2007 and targeted at mothers of Mexican descent in San Jose
[15].

A subject participating in the study must: 1) be a mother of Mexican descent; and 2) be
the parent of a child between the ages of 3 and 4.9. The trial data to be collected in this
case study will include the study subject’s BMI, 24-hour dietary recalls, household food
inventories, activity monitoring, household food security levels, and food purchase
motives.
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D. Implications for Trust-Building.
“Over time, by respecting the patient's culture and showing personal interest, a health
care provider can expect to win their confianza (trust)” [12]. If the solutions identified in
Section II are implemented, most of the trust influencers specific to the Hispanic
community will be addressed. Using culturally appropriate questions and translations can
address language barriers and the need to demonstrate respect through tactful
questioning. Recruiting community members as patient advocates addresses the need to
have personal relationships with researchers. Encouraging more physician referrals may
yield higher recruitment rates due to the loyalty and trust given to physicians by their
Hispanic patients. Ensuring general awareness in the community is a way to engage
family members and other decision influencers. Providing interim trial data to subjects
and giving them the opportunity to ask questions and get feedback empower the subjects
and demonstrate respect. Because trust issues specifically associated with the Hispanic
community can be addressed by the actions identified in Section II, no additional ones are
required here.
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IV Software Tools for Managing Clinical Trials

A. Commercial Software.
To successfully manage a clinical trial, general-purpose or specialized software is used
for trial planning, monitoring, management, execution, and administration. Clinical trial
management systems (CTMSs) focus on trial management, while clinical data
management systems (CDMSs) focus on the data associated with the clinical trial.
During the earlier phases of a clinical trial, internally developed software or generalpurpose software, such as spreadsheets, may be used. Later, as the number of
participants or tests increase, researchers may migrate to commercially available software
to obtain richer functionality [16], [17]. They may also engage external contract research
organizations (CROs) to manage trials on their behalf.

Although all clinical trials have some function requirements in common, many have their
own unique requirements [16]. This suggests that solution customization is an important
feature required by clinical researchers. They must be able integrate diverse software
packages to manage the full scope of a clinical trial. They also must be able to extend
and adapt existing software to accommodate their unique needs. Most existing software
packages provide this adaptability through import/export techniques, use of code
wrappers, or special purpose connectors. Cancer Biomedical Informatics Grid Clinical
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Trials Suite (caBIG1 CTS) [18] is a notable exception that is SOA-based, providing users
greater flexibility.

It should be noted that these existing software solutions focus on management of internal
clinical trial processes. With the exception of participant enrollment and management,
there are few built-in features available in the software to support trust-building activities.

B. Infrastructure Software.
In 2004, the NIH Roadmap funded twelve (12) contracts [19]-[30] that focused on the
development of an infrastructure of informatics, governance, and a common vocabulary
to facilitate cooperation among research groups. These contracts were part of the Clinical
Research Networks and National Electronics Clinical Trials and Research Network
(NECTAR) initiative. Refer to Appendix C for a summary of the final reports. Relevant
results of these contracts are summarized below:

The majority of projects developed systems focused on managing domain-specific data
[19]-[28] or establishing common vocabularies for information interchange within
existing networks [19]-[24], [30]. With the exception of CRN Harmony [25], these
systems were custom-built applications rather than commercial off-the-shelf (COTS)
ones. The resulting solutions created tighter alignment between the IT infrastructure and

1

caBIG is a registered trademark of the National Cancer Institute.
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local processes and procedures; but they might not be transferrable to other clinical
research organizations.

The InterTrial project [26] suggests that “conventional software tools can help with some
workflow problems… However, these tasks tend to represent only a small part of a
complex system… There are also fundamental problems that cannot be solved with
software alone. In the community practice sites studied, clinical research and patient care
are parallel but disconnected…” This suggests that there needs to be a focus on tools that
improve communications and infrastructure between clinical researchers and the
community.

Some projects were able to relate their results to changes in community interactions or
their ability to reach underserved populations. The Michigan Clinical Research
Collaboratory (MCRC) project [19] improved communication to primary care providers
(PCP) through extensions to the prompt and reminder system. The Health Maintenance
Organization Research Network Coordinated Clinical Studies Network (HMORN CCSN)
project [27] increased research participation by providing participating cardiologists
greater access to research information. The Electronic Primary Care Research Network
(ePRN) project [24] considered its ePCRN Gateway to be particularly suitable for
underserved areas by promoting greater communication and collaboration. The system
was being considered for use at Hispanic clinics in Los Angeles. The Research Involving
Outpatient Settings (RIOS) Net project [29] used community outreach that included
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Spanish-speaking staff; but it is not clear if this was through networked systems or via
face-to-face interactions.

C. Web Sites.
Currently, web sites are the primary software tool used by researchers to communicate
clinical trial information to the general public. Content on these sites can be from a
single source; or they can be portals that consolidate information from multiple sources.
The PDF web site [10] is an example of a portal site.

D. Summary of Tools.
In summary, progress has been made to develop common vocabularies or information
models to support clinical research. Web sites are used to provide information about
clinical research. Some solution developers are creating features to improve
communication among trial participants and provide easier access to research
information. However, the closed nature of the software architectures used by most
commercial vendors and researchers makes it difficult to customize or extend existing
solutions to support trust-building activity, leaving a high priority need unmet.

27

V Introduction to SOA and SOMA

In this section, key concepts of Service-Oriented Architecture (SOA) will be described
along with the benefits of using SOA within an enterprise. Next, the high-level steps of
Service-Oriented Modeling and Architecture (SOMA) will be covered. Finally, the
applicability of SOA and SOMA to the issue of trust-building in the clinical research
process will be explored.

A. Service-Oriented Architecture.
SOA is “an architectural style that supports service orientation. Service orientation is a
way of thinking in terms of services and service-based development and the outcomes of
services” [31]. It is focused on the construction of services that are aligned with business
concerns and can be combined to perform business processes within the context of an
enterprise [32]. These services may be developed internally or externally. They may be
shared, distributed, and reused across multiple organizations within an enterprise.

There are many definitions of SOA, some of which are conflicting [33]. However, there
are some ideas that all SOA definitions have in common, such as the concept of a service
and service composition, a services registry that provides information about available
services, and governance to manage creation and use of services.
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A service produces well-defined outcomes that are defined in a service contract. Service
providers perform the necessary actions to produce the outcomes; and service consumers
use those outcomes. Each service can stand alone, can be combined with other services,
or can be composed of other services. The actual service implementation is not visible to
consumers or other services that incorporate it. The services contract specifies how the
service provider and service consumer will interact.

A services registry is a mechanism for service providers to publish information about
available services to potential consumers. The registry typically contains details such as
services descriptions and policies.

SOA governance is concerned with the service life cycle and “focuses on the methods
and processes around service identification, funding, ownership, design, implementation,
deployment, reuse, discovery, access, monitoring, management, and retirement” [34].

One aspect that differentiates SOA from enterprise architecture (EA) is its emphasis on
aligning an enterprise’s business processes with its information technology (IT). A welldefined SOA establishes linkages from enterprise goals and business processes to
services. As goals or business processes change, SOA facilitates service reuse. The
loose coupling of services within an SOA provides IT organizations greater agility and
flexibility to meet enterprise needs.

29

Figure 1 depicts an SOA reference architecture, showing the various layers of building
blocks and how they relate to each other.

Figure 1. High-level view of an SOA reference architecture.

Starting from the bottom layer in Figure 1 and moving up, the operational systems layer
contains applications, infrastructure programs, and data that exist within the enterprise.
These are basic building blocks that are used to develop services. The service
components layer contains other programs that are used as intermediaries to decouple
services from the operational systems. For example, this layer would include program
wrappers to make operational systems available for use by systems. The services layer
contains services, services contracts, data used by services, and composite services. The
business processes layer contains business processes and information used by business
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processes. Last, the consumer layer contains users of the system and programs that
interface to services [31].

Immediately to the right of the services building blocks in Figure 1 and continuing to
move to the right, the integration layer enables the building blocks to communicate with
each other. The Quality of Service (QoS) layer is concerned with monitoring and
managing issues such as performance, security, and manageability. The information
layer contains building blocks for transforming and managing data. Last, the governance
layer contains rules and procedures for implementation and operational governance [31].

B. Why Use an SOA Approach.
A number of different architectural approaches were evaluated: 1) an entirely new
system could be developed; 2) existing systems could be extended; or 3) an architecture
could be developed that integrated new functionality with existing systems.

An ideal framework for architecting a software solution that supports trust-building
capabilities is one that lets the architect address key requirements for the solution,
including the following:
•

The system must be integrated with existing systems that are used by an
enterprise to manage clinical trials. This includes general-purpose software,
home-grown applications, or specialized CTMSs and CDMSs. Duplicate data and
function overlap should be minimized.
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•

The system must accommodate multiple CTMS and CDMS back-ends, since
communities may be involved in more than one clinical trial at any given time.

•

The system must be sufficiently flexible to accommodate the specific
requirements of each supported clinical trial. Trials may use different software
tools, have different types of stakeholders involved, or require different trustbuilding actions. Support for community-based research may have to
accommodate unique cultural, language, or interface requirements.

•

The system must support rapid deployment and be cost-effective.

Using an SOA will address these needs. The benefits include the following: 1) the use of
a service approach and loose coupling will enable easier integration with other systems;
2) the use of service composition allows the system to be customized and extended; 3)
specific needs of a given community can be addressed through tailored front-end
applications accessing common back-end services; 4) the ability to share development
and maintenance of the services means lower costs for information interchange; and 5)
the system will be transferable and reusable among a greater number of research
organizations.

C. Service-Oriented Modeling and Architecture.
There are several published methodologies for defining an SOA. The Service-Oriented
Modeling Framework (SOMF) and SOMA were evaluated for use in this study. SOMF
takes a service-first approach to discover and analyze service opportunities [35]. SOMA,
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on the other hand, supports both operation-first and service-first approaches. Since it was
anticipated that this solution would require development of new business processes, using
SOMA with an operation-first approach was deemed more appropriate.

In 2004, IBM2 announced SOMA as a methodology for identifying, specifying, realizing,
and implementing services, components, and their flows [35]. At that time, SOMA was
integrated with Global Services (GS) Method, a proprietary methodology. In 2006,
SOMA was integrated with IBM2 Rational Unified Process2 (RUP2), a commercially
available product. RUP is a flexible tool that allows an organization to define and
customize its processes. For example, it provides tailoring guidance on why certain
outputs are needed and when they can be omitted. As part of the integration effort,
SOMA tasks were modified to be more consistent with RUP.

Most recently, RUP has been subsumed by IBM Rational Method Composer3 (hereafter
referred to as Method Composer), another commercially available product that is Eclipsebased. Method Composer provides process descriptions, work breakdown structures that
identify required activities and tasks, artifact templates for work products, and guidelines
for usage. Support for SOMA is provided in RUP for SOMA (RUP/SOMA) Version 4.2,
a plug-in for Method Composer. There are some differences between RUP/SOMA and

2

IBM, Rational, Rational Unified Process, and RUP are trademarks or registered trademarks of
International Business Machines Corporation in the United States, other countries, or both.
3
Method Composer is a trademark or registered trademark of International Business Machines Corporation
in the United States, other countries, or both.
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SOMA methodologies. These differences are noted in Appendix D.

RUP/SOMA consists of three phases: 1) service identification; 2) service specification;
and 3) service realization. The purpose of service identification is to identify an initial set
of services that are aligned to business goals. Service identification can be performed
operation-first or service-first. In the operation-first approach, business processes are
modeled; and services are derived from those models. In the service-first approach,
classes and components are identified. Then operations are identified and added to the
classes. Services are identified through domain analysis [36].

Service identification consists of three major tasks: 1) domain decomposition; 2) goal
service modeling; and 3) existing asset analysis. The output from this phase is an initial
Service Model.

During the service specification phase, the structure of the service architecture is
developed and refined; and the Service Model is developed further. The Service Model
provides the external view of a particular service, such as its expected outcomes, how to
request the service, its dependencies, its service composition, and its messages. The goal
of this model is to design loosely coupled services that enable reuse [34].

The service realization phase focuses on an internal view of a service by using the Design
Model. This model represents how a service will be realized [34].
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A model resulting from a particular phase of RUP/SOMA can be traced to models in the
next or previous phase, thus providing traceability from the business processes to each
service. Refer to Appendix E for more information about the content of the Service
Model and the Design Model.
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VI Translating Needs to Software Requirements

Abstract needs such as trust and the solutions for building trust as described in Section II
are not specific enough to be able to derive a software functional specification. Before a
system can be architected, these high-level needs and the actions to address them must be
synthesized and refined to identify an implementable set of software requirements and to
ensure that the system does, in fact, address the original needs.

In this section an approach to translate needs into software requirements will be
demonstrated. This approach consists of five steps:
•

Problem Analysis - Needs are analyzed and grouped into common themes.

•

Solution Analysis – Suggested actions are mapped against problem themes; and
candidates for implementation via a software system are identified. Risk analysis
is performed against the candidates to understand which actions are most likely to
yield the most benefit and also to understand which actions carry the most risk to
implement.

•

Solution Mapping – Selected actions are mapped to existing business use cases;
and candidates for implementation are further refined.

•

System Conceptualization – A high-level external view of a proposed system is
defined. This view is used to define technical requirements via requirements
analysis.
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These steps and their relationship to a typical software development lifecycle are
illustrated in Figure 2.

Figure 2. Approach to map needs to requirements.

A. Problem Analysis.
Needs are elicited from domain experts and are usually expressed in an unstructured
manner and may be described in terms of problems to be solved. These descriptions may
be different facets of the same set of core problems, so the purpose of this first step is to
aggregate the problems into common problem themes. Table 1 shows the results of
aggregating the challenges associated with trust that were identified in Section II. Note
that each problem theme is given a unique number to permit traceability later.

Table 1. Results of Problem Analysis.
Problem Theme
T-1. Previous encounters

Problem
• Previous researchers did not follow through on
commitments.
• There is inadequate follow-up.
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T-2. Lack of understanding of
the research process

•
•
•

T-3. Ineffective informed
consent
T-4. Research relevancy

T-5. Loss of power/control

•
•
•
•

•
T-6. Quality of care

•
•

T-7. Lack of commitment to
community

•
•
•

T-8. Opinion of others

•
•
•

The research process is not thoroughly explained.
Candidate trial subjects misunderstand the difference
between research and medical care.
Candidate trial subjects fear loss of medical records
privacy.
Informed consent cannot be adequately performed due to
illiteracy or differences in language.
Research is not sensitive to candidate subject needs.
Research disregards the perspective of the community and
their needs and priorities.
No interim information is provided about study progress,
so candidate trial subjects cannot make informed
decisions.
The community cannot determine how data should be
collected or used.
Candidate trial subjects are skeptical of the quality of care
they will receive.
Treatments may not be consistent with trial subject values
or beliefs.
People may feel over-researched. They are sought out for
research but get limited access to healthcare.
There is inadequate follow-up. Researcher commitment
is only for the duration of the study.
Researchers are perceived as taking data without any give
back.
Candidate trial subjects may be aware of historical
mistreatment during clinical trials.
Candidate trial subjects are affected by attitudes of family
and friends.
Candidate trial subjects may be unwilling to go against
their personal physicians' wishes.

In Section II, it was noted that clinical trial referral rates by physicians have been low.
Because candidate trial subjects value and trust the guidance of their personal physicians
and healthcare providers, problems associated with engaging these professionals should
be considered when defining possible solutions for building trust between candidate trial
subjects and researchers.
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Additional problem themes associated with physician referrals are identified in Table 2.
Note that some of the themes are repeated from Table 1.

Table 2. Themes Associated with Physician Referrals.
Problem Theme
T-5. Loss of power/control

T-9. Lack of awareness or
understanding

T-10. Resource/time
demands

Problem
• Physicians fear their patients won't return after they are
referred.
• Referring physicians receive no feedback about the outcome
and/or status of their patients.
• Physicians are not aware of trials that are available to their
patients.
• Physicians do not understand the potential benefits and risks
to their patients of participating in clinical trials.
• Physicians lack awareness of clinical research and why it is
important.
• Physicians often have competing demands and concerns.
• Physicians are concerned about the administrative burden
associated with patient participation.

Additional problem themes can be derived by analyzing the trust-building solutions from
a community perspective, as described in Section II.C. These problem themes are
identified in Table 3.

Table 3. Themes from a Community Perspective.
Problem Theme
T-11. Inconsistent processes
and interfaces

Problem
• The clinical trials process is inconsistent across trials
being conducted in the community.
• There are multiple interfaces between candidate trial
subjects and researchers.
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B. Solution Analysis.
During this step, suggested actions are identified through techniques such as
brainstorming and then are mapped against the problem themes identified in the previous
step to ensure that all themes have been addressed. If an action is mapped to a problem
theme, it is considered to be a solution to that problem. As with problem themes, each
suggested action is given a unique number to permit traceability.

Figure 3 illustrates the mapping between problem themes and suggested actions. Note
that there is a many-to-many relationship between the themes and actions, as shown for
problem theme T-1 and action A-1.

Table 4 shows the initial results in a tabular format. Because the actions suggested in
Section II are based on trial stages, the table is divided into subsections corresponding to
each stage. Review of the table shows that all problem themes have been addressed.

Note that the NIH recommendations and solutions from a community perspective have
not been mapped to themes. This is because they are general policy statements and
cannot be mapped to specific trust issues.
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Figure 3. Mapping between problem themes and suggested actions.

Table 4. Results of Solution Analysis.
Trial
Stage
PrePlanning

Problem Theme

Suggested Action (Solution)

T-1. Previous
encounters
T-2. Lack of
understanding of
the research process
T-7. Lack of
commitment to
community
T-8. Opinion of
others

A-1. Increase awareness about clinical research and the
clinical trials process through education, outreach, and
advocacy.
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Planning

T-9. Lack of
awareness or
understanding
T-1. Previous
encounters
T-2. Lack of
understanding of
the research process
T-3. Ineffective
informed consent
T-4. Research
relevancy
T-5. Loss of
power/control

T-7. Lack of
commitment to
community
T-8. Opinion of
others

Execution

T-10.
Resource/time
demands
T-1. Previous
encounters
T-2. Lack of
understanding of
the research process
T-3. Ineffective
informed consent
T-5. Loss of
power/control

T-6. Quality of care
T-7. Lack of
commitment to

A-2. Educate physicians on the benefits to their patients
and themselves of participating in clinical trials.
A-3. Incorporate a community perspective in the clinical
trials process.
A-4. Build community awareness of researcher presence;
provide clinical trials education that is culturally
appropriate.
A-5. Use culturally appropriate questions and translations
to ensure comprehension and accessibility of informed
consent.
A-6. Incorporate community needs, patient perspectives,
priorities, issues, and concerns in trial design.
A-7. Include members of the community in all stages of
the clinical trials process for input, monitoring, and
decision-making. This includes participation on review
boards and data safety monitoring boards.
A-6. Incorporate community needs, patient perspectives,
priorities, issues, and concerns in trial design.
A-8. Engage and train research advocates to participate in
all stages of the clinical trials process, including subject
recruitment.
A-9. Engage community physicians and healthcare
providers as study investigators or by utilizing their
facilities.
A-10. Ensure follow-through on commitments to trial
subjects.
A-11. Ensure ongoing one-on-one communication with
trial participants throughout the trial and be responsive to
concerns.
A-5. Use culturally appropriate questions and translations
to ensure comprehension and accessibility of informed
consent.
A-11. Ensure ongoing one-on-one communication with
trial participants throughout the trial and be responsive to
concerns.
A-7. Include members of the community in all stages of
the clinical trials process for input, monitoring, and
decision-making. This includes participation on review
boards and data safety monitoring boards as well as
involvement in gathering, analyzing, and disseminating
information.
A-12. Provide health education to trial subjects that is
sensitive to cultural values and beliefs.
A-12. Provide health education to trial subjects that is
sensitive to cultural values and beliefs.
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community
T-8. Opinion of
others

Outcome

T-11. Inconsistent
processes and
interfaces
T-7. Lack of
commitment to
community

A-11. Ensure ongoing communication to the communityat-large throughout the trial.
A-8. Engage and train research advocates to participate in
all stages of the clinical trials process, including subject
recruitment.
A-13. Provide a single consistent interface between the
community and different researchers.
A-14. Disseminate project outcomes.

C. Solution Mapping.
Next, the actions or solutions defined in the previous step are mapped to existing business
processes. Mapping an action to a business process implies that the business process will
incorporate that action. If an appropriate existing business process cannot be identified
for an action, a new business process must be created.

This study will use a business architecture model for clinical trials that has been
developed by caBIG [37] to identify existing business processes. Table 5 shows the
mapping and indicates if a new process must be defined or if an existing one must be
modified.

Table 5. Mapping Proposed Solutions to Business Processes.
Solution
A-1. Increase awareness about clinical
research and the clinical trials process
through education, outreach, and advocacy.

Add or Modify Process
Add a community outreach
process. Target media,
policy makers, healthcare
providers, and the
community-at-large.
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Business Process
Perform Outreach

A-2. Educate physicians on the benefits to
their patients and themselves of
participating in clinical trials.

A-3. Incorporate a community perspective
in clinical trials process.

A-4. Build community awareness of
researcher presence; provide clinical trials
education that is culturally appropriate.

A-5. Use culturally appropriate questions
and translations to ensure comprehension
and accessibility of informed consent.

A-6. Incorporate community needs, patient
perspectives, priorities, issues, and
concerns in trial design.
A-7. Include members of the community in
all stages of the clinical trials process for
input, monitoring, and decision-making.
This includes participation on review
boards and data safety monitoring boards.
A-8. Engage and train research advocates
to participate in all stages of the clinical
trials process, including subject
recruitment.

A-9. Engage community physicians and
healthcare providers as study investigators
or by utilizing their facilities.
A-10. Ensure follow-through on
commitments to trial subjects.

Add a community outreach
process. Target media,
policy makers, healthcare
providers, and the
community-at-large.
Modify processes per other
business requirements.

Add a community outreach
process. Target media,
policy makers, healthcare
providers, and the
community-at-large.
Modify Plan Study and
Initiate Study processes to
incorporate tasks to make
them more culturally
appropriate.
Modify Plan Study
processes to include input
from community members.
Modify Plan Study
processes to include
participation by community
members.
Add new business processes
to manage patient advocate
recruitment, training, and
registration.
Add a new business process
to register a patient advocate
for a trial.
Add a new business process
for referral from the
Enrolling Physician.
Modify Plan Study
processes to include
consideration of community
members.
not applicable
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Perform Outreach

All existing
business
processes, where
appropriate
Perform Outreach

All informed
consent processes

All existing
business
processes, where
appropriate
All existing
business
processes, where
appropriate
Manage Patient
Advocates

Register Patient
Advocate
Refer Subject

All existing
business
processes, where
appropriate
not applicable

A-11. Ensure ongoing one-on-one
communication with trial participants
throughout the trial and be responsive to
concerns.
A-12. Provide health education to trial
subjects that is sensitive to cultural values
and beliefs.

Add a new business process
to permit monitoring and
Q&A by study subjects and
their enrolling physicians.
Add a new business process
to provide health education
during a clinical trial.

A-13. Provide a single consistent interface
between the community and different
researchers.
A-14. Disseminate project outcomes.

not applicable

not applicable

Add a new business process
to communicate outcomes to
the community.

Disseminate Trial
Results

Monitor Study
Obtain Trial Data

Provide Health
Education

In most cases, trust-building activities can be incorporated into the model by updating
existing business processes. However, some new business processes are needed to define
interactions with the community. Also, two new business processes, Perform Outreach
and Manage Post-Study, have been identified to manage activities before and after
clinical trials, respectively. The Business Process column shows “not applicable” if the
corresponding business requirement describes an action that is more effectively
implemented through some means other than a business process.

D. System Conceptualization.
A view of the new business processes and their relationships to existing ones is then
developed. The results are shown in Figure 4. Manage Community is shown as a
separate group of new business processes that manages interactions between the
community and clinical trials personnel. This approach shields the community from
differences in business processes used by various researchers who may be operating
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within the community and from different clinical trial systems used for managing trials of
interest.

The roles on the left side of the figure correspond to major actors involved in the
processes. The boxes on the right represent systems used by clinical trials personnel.
The arrows represent the flow of information between actors, processes, and systems.

Figure 4. Interaction between new and existing business processes.

E. Requirements Analysis.
Using the external view defined in the previous step, more detailed technical
requirements can be developed. Requirements for each of the processes are shown in
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Table 6. Requirements have not been specified for Perform Outreach or Provide Health
Education because they will be specific to the implementing organization.

Table 6. Manage Community Requirements.
Req ID
CR1
CR1.1
CR1.1.1

CR1.1.2
CR1.2
CR1.2.1
CR1.2.1.10
CR1.2.1.20
CR1.2.1.30
CR1.2.1.40
CR1.2.2
CR1.2.2.10
CR1.2.2.20
CR1.2.2.30
CR1.2.2.40
CR1.2.3
CR1.2.3.10
CR1.2.3.20
CR1.2.3.30
CR1.3

Description
The system shall support the Manage Community process.
The system shall support the Manage Patient Advocates process
The Manage Patient Advocates subsystem shall provide a way for a
community research coordinator to create, retrieve, update, or delete (CRUD)
contact information about patient advocates and enrolling healthcare
providers within the community.
The Manage Patient Advocates subsystem shall provide a way to register a
patient advocate for a particular clinical trial.
The system shall support the Refer Subject process
The Refer Subject subsystem shall provide shall provide information about
clinical trials being conducted in the community.
The Refer Subject subsystem shall provide a list of clinical trials that are
currently seeking participants.
The Refer Subject subsystem shall provide a description of a selected active
clinical trial.
The Refer Subject subsystem shall list eligibility requirements for a selected
active clinical trial.
The Refer Subject subsystem shall provide information about benefits and
risks of participating in a selected active clinical trial.
The Refer Subject subsystem shall provide a way for a patient advocate or
enrolling physician to refer a subject to a trial.
The Refer Subject subsystem shall provide a way to list all candidates
associated with a patient advocate and the status of each candidate.
The Refer Subject subsystem shall provide a way to create, retrieve, update,
or delete (CRUD) information about a candidate subject.
The Refer Subject subsystem shall provide a way to submit a candidate for
consideration.
The Refer Subject subsystem shall provide a way to link each candidate to
the enrolling patient advocate or physician.
The Refer Subject subsystem shall provide a way to register candidates for an
active trial.
The Refer Subject subsystem shall provide a way for a site registrar to
review all candidates for a trial.
The Refer Subject subsystem shall provide a way for a site registrar to
determine if the candidate meets eligibility requirements.
The Refer Subject subsystem shall provide a way for a site registrar to
register a selected candidate for a trial.
The system shall support the Monitor Subject process
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CR1.3.1
CR1.3.1.10
CR1.3.1.20
CR1.3.1.30
CR1.3.1.40
CR1.3.2
CR1.3.2.10
CR1.3.2.20
CR1.3.2.30
CR1.3.2.40
CR1.4
CR1.4.1
CR1.4.2
CR1.4.3
CR1.4.4
CR.1.5
CR1.5.1
CR1.5.2
CR2
CR2.1
CR2.2
CR3
CR3.1
CR3.2
CR4
CR5

The Monitor Subject subsystem shall provide a way for a trial subject to
monitor his or her progress during a trial.
The Monitor Subject subsystem shall provide a way to request a report of
the subject’s trial data.
The Monitor Subject subsystem shall provide a report of a subject’s trial
data.
The Monitor Subject subsystem shall provide a way to submit an ad hoc
question.
The Monitor Subject subsystem shall provide a way to respond to an ad hoc
question.
The Monitor Subject subsystem shall provide a way for an enrolling
healthcare provider to monitor a patient’s progress during a trial.
The Monitor Subject subsystem shall provide a way to request a report of
the subject’s trial data.
The Monitor Subject subsystem shall provide a report of a selected subject’s
trial data.
The Monitor Subject subsystem shall provide a way to submit an ad hoc
question.
The Monitor Subject subsystem shall provide a way to respond to an ad hoc
question.
The system shall support the Monitor Trial Data process
The Monitor Trial Data subsystem shall provide a way to request a report of
the trial status.
The Monitor Trial Data subsystem shall provide report of trial status.
The Monitor Trial Data subsystem shall provide a way to submit an ad hoc
question.
The Monitor Trial Data subsystem shall provide a way to respond to an ad
hoc question.
The system shall support the Disseminate Trial Results process.
The Disseminate Trial Results process shall provide a way to request a report
of trial results.
The Disseminate Trial Results process shall provide a study results report.
The system shall be accessible via the Internet.
The system shall be accessible through standard browsers on Windows and Mac
clients.
The system shall be accessible through mobile devices.
The system shall provide a secure environment.
The system shall meet all applicable government regulations for privacy and
security.
The system shall support authentication and authorization.
The system shall provide translated information, where appropriate, to ensure
informed consent.
The system shall support multiple, concurrent active trials.
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VII An SOA-Based Solution to Build Trust

Now that technical requirements have been defined, the design phase of the software
development lifecycle can begin. During this phase, the architecture is developed.

The RUP/SOMA methodology, as defined by IBM Rational Method Composer Version
7.5.0.1 [36], will be used to architect and model a solution for increasing trust between
the San Jose Hispanic community and clinical researchers. It will be used as the basis for
determining the process phases and activities to be followed. Each task in the
RUP/SOMA work breakdown structure corresponds to a subsection in this section. If
there are templates or alternative modeling notations defined in the original SOMA
methodology, they will be given preference over RUP/SOMA. Any deviations, such as
modeling notations, from the RUP/SOMA methodology will be noted.

Because most clinical trials use some form of information technology to manage their
processes, the assumption of this study is that any new services must fit within the
context of existing systems. In 2008, the National Cancer Institute launched an
information initiative to encourage collaboration among the cancer community. To that
end, they created the Cancer Biomedical Informatics Grid (caBIG) [38]. This initiative
includes activity to architect and develop a clinical trials management system based on
open standards, including SOA, to support cross-organization collaboration [39]. For this
study, caBIG will be used as the basis for any enterprise-level modeling that must be
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created as part of implementing the RUP/SOMA methodology.

A. Service Identification.
This is the first phase of RUP/SOMA. During this phase, the Service Model and GoalService Model are developed. To ensure alignment of business processes to services, an
operation-first approach will be used. Service Identification consists of Domain
Decomposition, Goal-service Modeling, and Existing Asset Analysis activities.

1) Domain Decomposition: This activity is used to identify candidate services and
associated service flows. It is performed top-down to ensure that services that align with
the business. This step is also used to understand the relationships among different
business functions within a business to identify commonalities where services may be
shared. Table 7 summarizes the tasks and their inputs and outputs.

Table 7. Domain Decomposition Tasks, Inputs, and Outputs.
Task
Function area analysis

Inputs
Business Domain

Refine a business use case

Business Actor
Business Use Case
Business Use Case
Model
Business Analysis Model Service Model
Business Analysis Model Service Model
Service Model

Business process analysis
Business use case analysis
(SOA)
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Outputs
Business Analysis Model
Business Architecture
Document
Business Actor
Business Use Case
Business Use Case Model

a) Functional area analysis: The purpose of this task is to partition a business into its
functional areas and to understand the relationships among them. The outputs are a
Business Analysis Model and a Business Architecture Document. The Business Analysis
Model is an abstraction of the business and shows how business workers, business
entities, and business systems interact to fulfill the goals of that business. The Business
Architecture Document provides a comprehensive view of the business and is used to
describe the structure of the business, including its organizational structure and how
responsibilities and business work are allocated within that structure.

Per RUP/SOMA guidelines, if the objective of the project is to specify a needed behavior,
a Business Analysis Model is not required. The Business Architecture Document serves
as the basis for making informed decisions about a project and does not directly affect the
architecture of the information technology solution itself. Because the project is focused
on trust-building, a specific behavior, and is of interest to only one business function,
these two work products will not be produced for this study.

However, some general comments about business functions and the role that the clinical
trials function plays within a business will be covered briefly here. This information can
be used when investigating opportunities for service reuse, either as a consumer or as a
provider, and when deciding on service ownership.
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If a business has public relations, communications, or marketing/sales functions, those
functions may already be involved in activities associated with community outreach or
with local physicians and other healthcare providers who are their customers. If so, the
systems they use should be explored to determine if there is potential for service reuse.
For this study, the assumption is that no other functions within the business have systems
that can be reused.

The role of the clinical trials function within a business will depend on the purpose of that
business. For example, it would be a supporting function in a business that develops
drugs or treatments for commercial use; whereas it would be the primary function in a
research organization. It would be the core business for a contract research organization
that manages clinical trials on behalf of outside researchers. Thus, the question of
ownership must be decided on a specific case-by-case basis.

Although RUP/SOMA is only focused on internal functional areas, it is also important to
understand how the business interacts with external entities that are critical to the success
of the business. In the case of this study, volunteers for clinical trials and their
communities perform a function that is vital to any business that requires clinical trials.
Therefore, the business architecture should also consider the role of communities within
their business.
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b) Refine a business use case: The purpose of this task is to refine existing business use
cases so they contain sufficient detail to be realized. The outputs are Business Actor,
Business Use Case, and Business Use Case Model for each refined business use case.

Inputs to this task are Business Actor, Business Use Case, and Business Use Case Model.
RUP/SOMA assumes these inputs were created at an earlier point in time; and it does not
include tasks for creating them in the work breakdown structure. The caBIG CTMS
architecture model [37] defines business actors, business processes, and business use
cases in sufficient detail to permit realization, so no additional work is required for this
step. Refer to Appendix G to see the subset of business use cases that are relevant to this
study.

c) Business process analysis: The purpose of this task is to analyze business processes
to identify candidate services. In this task, business processes are decomposed into more
and more levels of detail until user interfaces start being considered. The most detailed
levels are considered leaf-level sub-processes and are candidates for services. The output
is an initial version of the Service Model where the service portfolio is identified and
organized into a service hierarchy.

This task should consider both existing and new business processes. Refer to Appendix
G to see the new business processes. The initial analysis is shown in Figure 5, Figure 6,
and Figure 7, using a SOMA notational form to show the relationship between business
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processes and services. Business processes and their flows are represented in the
Business Aspect; and use cases are represented by bubbles in the IT Aspect. Due to the
large number of sub-processes in this domain, only new sub-processes are shown. On an
actual project, all sub-processes would be included in the analysis. This would ensure
that the relationships between the business and IT are maintained.

Figure 5 shows the highest level of business processes. Figure 6 shows the
decomposition of the first three processes. Figure 7 shows the decomposition of the last
two processes. RUP/SOMA states that the mapping between use cases and services are
typically one-to-one. Note that services have not been defined for Perform Outreach and
Provide Health Education business processes because they are not expected to have
significant IT requirements. Obtain Trial Results does not appear because it is not
specifically associated with a business process.
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Figure 5. Top-level business processes.

Figure 6. Sub-processes and use cases - Part 1.
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Figure 7. Sub-processes and use cases - Part 2.

Although not required by RUP/SOMA at this point, it is useful to repeat Step b) to refine
the new business use cases so there is sufficient information for realization. These are
defined in Appendix H.

After refinement of the new business use cases some changes have been identified:
•

Manage Patient Advocates has been decomposed into two business use cases,
Recruit Patient Advocate and Train Patient Advocate. A service will not be
created for Train Patient Advocate, since implementation will have minimal IT
requirements.

•

Refer Subject has been decomposed into three business use cases, Manage Trial
Candidate, Request Subject Referral, and Manage Referral Request.
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•

Obtain Trial Data has been added to the Report and Analyze Study Category.

RUP/SOMA uses a service hierarchy to organize services into a classification scheme.
The caBIG classifications will be used to facilitate better integration with the caBIG
architecture because they roughly approximate the different functions associated with
clinical trials. Figure 8 shows the service classification hierarchy for candidate services
based on the results of business process analysis.

Figure 8. Service Model: service hierarchy.

RUP/SOMA provides a template for capturing information about services that will be
used to support service identification and service specification. During the service
identification phase, the primary concerns are mapping services to business functions and
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goals, identifying existing assets, and noting the status of the service. Table 8 is a
completed template for the services that have been identified in Figure 8. At this point,
all services are in candidate status, so all services have a status of “C.”

Table 8. Service Model: Service Portfolio After Business Process Analysis.
Service

Recruit Patient
Advocate
Register Patient
Advocate
Manage Trial
Candidate
Request Subject
Referral
Manage Referral
Request
Monitor Subject

Monitor Trial
Data
Obtain Trial
Data
Disseminate
Trial Results

Description

Manage potential patient advocate.

Status Associations
Function /
Process
C
Pre-Study

Register patient advocate as participant C
in clinical trial.
Manage potential subject, including
C
information about him/her.
Request to register subject into a trial
C

Initiate Study

Review request to register subject into
a trial.
Generate a view of trial data for a
specified subject, submit questions,
and review answers.
Generate a view interim trial data.

C

Conduct Study

C

Conduct Study

C

Conduct Study

Query CDMS to retrieve data.

C

Send a final report in a format that can
be viewed.

C

Report and
Analyze Study
Post-Study

Goal Asset

Conduct Study
Conduct Study

d) Business use case analysis (SOA): The purpose of this task is to review business use
cases to identify and refine the candidate services. Reviewing the set of operations for a
business use case realization may reveal some services that are conversational in nature.
In those cases, the architect should consider aggregating those services into a single one.
The output is an updated Service Model. After review of the business use cases, none
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have been identified to be conversational. As a result, no changes are required.

2) Goal-Service Modeling: This activity is used to determine which services will help
the business achieve desired goals and to identify where there may be a services gap.
Metrics are defined to measure how well services perform against those business goals.
A Goal-Service Model is created to map business goals to specific metrics and services.
Table 9 summarizes the tasks and their inputs and outputs.

Table 9. Goal-Service Tasks, Inputs, and Outputs.
Task
Inputs
Outputs
Identify business goals and KPIs
Business Vision Business Goal
Identify and associate services to goals Business Goal
Goal-Service Model
Service Model

a) Identify business goals and KPIs: The purpose of this task is to identify the goals
that are relevant to the project and to identify ways to measure the effectiveness of the
services being developed to meet those goals. The output is Business Goal, a hierarchical
list of goals and one or more key performance indicators (KPIs) for each goal.

As discussed in Section II, lack of trust between clinical researchers and the communities
where they operate can impact the ability to recruit and retain subjects in clinical trials.
This, in turn, affects the total cost of a clinical trial. Figure 9 reflects this linkage.
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Note that some goals do not have KPIs. This is because it may be difficult to measure
that specific goal. In these cases, the KPI for a goal higher or lower in the hierarchy can
serve as an indirect KPI. Also note that this is not a strict hierarchy. Goals 1.1.1, 1.2.1,
and 2.2.1 are identical and show that implementing a single sub-goal can help an
organization achieve multiple higher-level goals. Finally, note that this is only a subset
of goals that a business might have. Only those that are relevant to the project are shown.

The specific percentage improvements in goals 1, 1.2, and 2.2 should be determined by
the sponsoring organization. For this study, placeholders have been used.

Figure 9. Business goal hierarchy.
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Because these business processes focus on the interactions between researchers and the
community, the services must also be effective in helping the community meet their
goals. Community goals are focused on improving the health of community members, as
shown in Figure 10.

Figure 10. Community goal hierarchy.

b) Identify and associate services to goals: The purpose of this task is to link services to
business goals. The output is a Goal-Service Model in tabular form that maps the
information from Business Goal in Figure 9 and Figure 10 to specific metrics and
services, as shown in Table 10. Note that services related to recruitment and patient
referral are mapped to the community goal. This is based on the assumption that
participation in relevant clinical trials can result in effective treatment of health concerns.

Table 10. Preliminary Goal-Service Model.
Goal or Sub-Goal
1: Reduce clinical trial
costs.
1.1: Improve trial subject
recruitment rates.

KPIs
Reduce clinical trial
costs by w%.
X% increase in the
number trials that
successfully enroll
the required number
of eligible subjects
within the planned
recruitment period.
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Metric
Record recruitment
spending.
Record planned
enrollment time
lines versus actual.

Services

Manage Trial
Candidate
Request Subject
Referral
Manage Referral
Request

1.1.1: Increase trust
between clinical
researchers and the
communities where they
operate.
1.2: Improve trial subject
retention rates.
1.2.1: Increase trust
between clinical
researchers and the
communities where they
operate.
2: Improve quality of
trial data.
2.1: Improve quality of
data submitted by trial
subjects.

2.1.1: Increase trust
between clinical
researchers and the
communities where they
operate.
3: Receive effective
treatment for a health
concern.

Reflected in KPI for
Goal 1.1.

n/a

Reduce drop-out rate Record status of
by y%.
each subject
enrolled in a trial.
Reflected in KPI for n/a
Goal 1.2.

Reflected in KPI for
Goal 2.1.
Reduce the number
of trial data points
that must be omitted
from the study by
z%.
Reflected in KPI for
Goal 2.1

Recruit Patient
Advocate
Register Patient
Advocate
Monitor Subject
Monitor Trial Data
Obtain Trial Data
Disseminate Trial
Results

n/a
Record status of data Recruit Patient
points for a given
Advocate
trial subject.
Register Patient
Advocate
Monitor Subject
n/a
Obtain Trial Data
Disseminate Trial
Results

Medical condition is Recorded as part of
cured or successfully trial execution.
managed.
Identified during
trial planning.

Recruit Patient
Advocate
Register Patient
Advocate
Manage Trial
Candidate
Request Subject
Referral
Manage Referral
Request
Monitor Subject
Monitor Trial Data

3) Existing Asset Analysis: This activity is used to identify existing assets. Table 11
summarizes the tasks and their inputs and outputs.
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Table 11. Existing Asset Analysis Tasks, Inputs, and Outputs.
Task
Existing asset analysis
Data model analysis
Business rule analysis
Construct Architectural Proof-of-Concept (SOA)

Inputs
Service Model
Service Model
Service Model
Service Model

Outputs
Service Model
Service Model
Service Model

a) Existing asset analysis: The purpose of this task is to review existing applications to
identify candidate services for the solution. For this task, the business application
portfolio is examined to understand the functionality the applications provide. This
application portfolio includes custom applications and COTS. A coarse-grained mapping
of business functions to services is performed to identify candidate services from these
applications. The output is an updated Service Model.

For this study, it is assumed that the caBIG systems are the only ones in the business that
have relevant applications. There are three caBIG systems that are used in this study.
caBIG Clinical Trial Suite 2.0 (CTS) [18] is a services-based system for use at clinical
trial sites. caGrid 1.3 [40] is the underlying platform and infrastructure that integrates
caBIG tools and provides common services such as authorization and authentication.
caBIG Integration Hub [41] is a service bus that manages access to services provided by
components of CTS. The specific services that are available are documented at caBIG
Knowledge Center [42].
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Based on this assumption, the Service Model has been updated with additional candidate
services, Patient and Registration. These are shown in bold type in Table 12. Although
not explicitly included in the RUP/SOMA methodology, the Goal column has been
updated with goals from the goal hierarchies in Figure 10 and Figure 11, since that
information is now available.

Table 12. Service Model: Service Portfolio After Existing Asset Analysis.
Service

Description

Status Associations
Function /
Process
C
Pre- Study

Recruit Patient
Advocate

Manage potential patient advocate.

Register Patient
Advocate

Register patient advocate as
participant for a trial.

C

Initiate Study

Manage Trial
Candidate
Request Subject
Referral
Manage Referral
Request
Monitor Subject

Manage potential subject, including
information about him/her.
Request to register subject into a trial

C

Conduct Study

C

Conduct Study

Review request to register subject into C
a trial.
Generate a view of trial data for a
C
specified subject, submit questions,
and review answers.
Generate a view interim trial data.
C

Conduct Study

Monitor Trial
Data
Obtain Trial
Data
Disseminate
Trial Results
Patient
Registration

Generate a report of trial data or
C
outcomes.
Send a final report in a format that can C
be viewed.
Manage and query patients.
C
Manage and query registration.
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C

Conduct Study

Conduct Study
Report and
Analyze Study
Post-Study
Conduct
Study
Conduct
Study

Goal Asset
1.1.1
2.1
3
1.1.1
2.1
3
1.1
3
1.1
3
1.1
3
1.2
2.1
3
1.2
3
1.2.1
2.1.1
1.2.1
2.1.1
1.2 CTS
1.1

CTS

b) Data model analysis: The purpose of this task is to examine the business domain
model to identify additional candidate services for the solution. The domain model is
examined for business entities that overlap with those of the solution domain. By
identifying the systems that operate on those entities within the business, one may find
other applications that are candidates for services. The output is an updated Service
Model.

Because this study assumes that CTS is the only system with relevant applications, no
additional candidate services have been added.

c) Business rule analysis: The purpose of this task is to examine the business rules to
identify additional candidate services for the solution.

Business rules are examined to determine if any can be externalized via a service.
Externalizing these rules from the logic will allow the rules to evolve independently
without affecting the application logic, thus removing variability. The output is an
updated Service Model.

Trial eligibility criteria are business rules to determine if a prospective subject meets the
requirements to participate in a clinical trial. These criteria are unique to each clinical
trial. An application that automatically evaluates the eligibility of a prospective subject
would be a candidate service. However, at the time the study was conducted, CTS did
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not have such an application or service, so there is no change to the Service Model.

d) Construct architectural proof-of-concept: The purpose of this task is to develop a
prototype of the architecture or a conceptual architecture to evaluate its feasibility.
In the proof-of-concept, non-functional requirements, such as exception handling and
data availability, are evaluated to determine if the proposed solution is feasible. No
output is defined for this task.

A conceptual architecture is illustrated in Figure 11. Access to web services will be
through caBIG Integration Hub, which is an enterprise service bus based on open
standards [41]. Exception handling and message conversions will be handled by caBIG
Integration Hub. Data associated with a trial will be in a separate CDMS. caBIG
Integration Hub can access these CDMSs through a Clinical Connector. At the time of
this study, four popular CDMSs were being evaluated for implementation. This study
assumes that a supported CDMS will be used for implementing the solution.
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Figure 11. Conceptual architecture.

B. Service Specification.
This is the second phase of RUP/SOMA. During this phase, the Service model is
updated to document service exposure decisions, to identify interdependencies among
services, and to define service messages. The Design Model is developed to provide
greater details about services and to describe the components of the solution and
relationships among them. Service Specification consists of Perform Service
Specification, Perform Subsystem Analysis, and Perform Component Specification.

1) Perform Service Specification: This activity is used to further specify the services.
Table 13 summarizes the tasks and their inputs and outputs.
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Table 13. Perform Service Specification Tasks, Inputs, and Outputs.
Task
Apply services litmus
tests
Service specification
Message design
Identify security patterns

Inputs
Service Model
Service Model
Service Model
Software Architecture
Document

Outputs
Goal-Service Model
Service Model
Service Model
Service Model
Software Architecture
Document

a) Apply services litmus tests: The purpose of this task is to select which of the
candidate services are to be exposed. The outputs are an updated Goal-Service Model
and an updated Service Model.

For this task, each candidate service is evaluated against a set of criteria:
•

Is the service aligned with the business?

•

Is the service composable? For example, is the service stateless and is it selfcontained? Is it technology neutral?

•

Does the service have an external description? This would be applied to existing
applications.

•

Can this service be reused?

•

Is the service technically feasible?

Candidates that do not meet all these criteria will not typically be exposed. However, this
evaluation is an iterative process, so the decision may change as more information about
eliminated services is discovered. Regardless, the eliminated services will still be
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implemented in some manner, perhaps as applications on top of service components or as
internal services.

Table 14 maps each candidate service against the criteria. Note that there are a number
of services that will be exposed, even though they do not meet the external description
criteria. This is because these services have not been implemented yet and external
descriptions do not exist. While performing this task, it was noted that Register Subject
duplicates an existing service, so this service will not be exposed at this time.

Table 14. Service Model: Service Exposure Decision.
Service

Expose Service Litmus Test Results
Aligned Composable External
Reusable Feasible
Description
Recruit Patient Y
x
x
x
x
Advocate
Register
Y
x
x
x
x
Patient
Advocate
Manage Trial Y
x
x
x
x
Candidate
Request
N
x
x
Subject
Referral
Manage
N
x
x
Referral
Request
Monitor
N
x
x
Subject
Monitor Trial N
x
x
Data
Obtain Trial
Y
x
x
x
x
Data
Disseminate
N
x
x
x
Trial Results
Patient
Y
x
x
x
x
x
Registration
Y
x
x
x
x
x
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Comments
new service
new service

new service
new service

new service

new service
new service
new service
new service

Based on the litmus test, the Service Model is updated, as shown in Table 15, where the
Status column has been updated to be either “A” to indicate the associated service has
been approved for implementation or “E” to indicate the associated service will be
exposed. The Services column in the Goal-Service Model is updated, as shown in Table
16.

Table 15. Service Model: Service Portfolio After Litmus Test.
Service

Description

Status Associations
Function /
Process
Pre- Study
E

Recruit Patient
Advocate

Manage list of potential patient
advocates.

Register Patient
Advocate

Register patient advocate as participant E
in clinical trial.

Initiate Study

Manage Trial
Candidate
Request Subject
Referral
Manage Referral
Request
Monitor Subject

Manage list of potential subjects,
including information about them.
Request to register subject into a trial

E

Conduct Study

A

Conduct Study

Review request to register subject into
a trial.
Generate a view of trial data for a
specified subject, submit questions,
and review answers.
Generate a view interim trial data.

A

Conduct Study

A

Conduct Study

A

Conduct Study

Generate a report of trial data or
outcomes.
Send a final report in a format that can
be viewed.
Manage and query patients
Manage and query registration

E
A

Report and
Analyze Study
Post-Study

E
E

Conduct Study
Conduct Study

Monitor Trial
Data
Obtain Trial
Data
Disseminate
Trial Results
Patient
Registration

70

Goal Asset
1.1.1
2.1
3
1.1.1
2.1
3
1.1
3
1.1
3
1.1
3
1.2
2.1
3
1.2
3
1.2.1
2.1.1
1.2.1
2.1.1
1.2 CTS
1.1 CTS

Table 16. Goal-Service Model After Litmus Test (Exposed Services Only).
Goal or Sub-Goal
1: Reduce clinical
trial costs.

KPIs
Reduce clinical trial costs by
w%.

1.1: Improve trial
subject recruitment
rates.

X% increase in the number
trials that successfully enroll
the required number of
eligible subjects within the
planned recruitment period.
Reflected in KPI for Goal 1.1.

1.1.1: Increase trust
between clinical
researchers and the
communities where
they operate.
1.2: Improve trial
subject retention
rates.
1.2.1: Increase trust
between clinical
researchers and the
communities where
they operate.
2: Improve quality of
trial data.
2.1: Improve quality
of data submitted by
trial subjects.
2.1.1: Increase trust
between clinical
researchers and the
communities where
they operate.
3: Receive effective
treatment for a health
concern.

Reduce drop-out rate by y%.

Metric
Record
recruitment
spending.
Record planned
enrollment time
lines versus
actual.
n/a

Services

Manage Trial
Candidate

Recruit Patient
Advocate
Register Patient
Advocate

Reflected in KPI for Goal 1.2.

Record status of
each subject
enrolled in a trial.
n/a

Reflected in KPI for Goal 2.1.

n/a

Reduce the number of trial
data points that must be
omitted from the study by z%.

Record status of
data points for a
given trial
subject.
n/a

Recruit Patient
Advocate
Register Patient
Advocate

Recorded as part
of trial execution.
Identified during
trial planning

Recruit Patient
Advocate
Register Patient
Advocate
Manage Trial
Candidate

Reflected in KPI for Goal 2.1.

Medical condition is cured or
successfully managed.

b) Service specification: The purpose of this task is to define each service in greater
detail, including the service dependencies, composition, flows, and non-functional
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requirements. The output is a Service Model that is updated with this information.

RUP/SOMA defines two types of dependencies, functional ones and temporal ones.
When a service is a composition of other services, the composing service has a functional
or Type 1 dependency on the composed services. When services are used in the context
of business processes, the services may have to be executed in a particular order. These
services have temporal or Type 2 dependencies and need to be choreographed.

None of the new exposed services have Type 1 dependencies. Manage Referral Request
has Type 1 dependencies on Patient and Registration. However, it is has not been
earmarked as an exposed service. The temporal dependencies are shown in Figure 12
using a SOMA notational form.

Figure 12. Service Model: temporal (Type 2) dependencies.
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Service composition is used to group together a set of short-running non-interruptible
processes or a set of long-running processes. In this study, composition is not required
since these processes are short-running and interruptible.

Nonfunctional requirements, such as availability, operational window size, response time,
and peak throughput, are considerations that should be noted. The services in this study
do not have nonfunctional requirements beyond typical web application response times.

c) Message design: The purpose of this task is to develop a message design model that
describes the message exchange patterns. The output is an updated Service Model that
identifies the operations for each service along with its signature.

The RUP/SOMA template requires a separate table for each service. To preserve space,
a different format containing the same information was used. Table 17 includes
messages for each new exposed service.

Table 17. Service Model: Service Messages.
Service
Recruit Patient
Advocate

Register Patient
Advocate

Manage Trial
Candidate

Topic
createPatientAdvocate
updatePatientAdvocate
deletePatientAdvocate
findPatientAdvocate
createRegistration
updateRegistration
deleteRegistration
findRegistration
createSubject
update Subject

Input Message
PatientAdvocate
PatientAdvocate
PatientAdvocate
PatientAdvocate
AdvocateRegistration
AdvocateRegistration
AdvocateRegistration
AdvocateRegistration
Subject
Subject
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Output Message
PatientAdvocate
PatientAdvocate
PatientAdvocate
PatientAdvocate
Subject

Obtain Trial Data

deleteSubject
findSubject
getSingleSubject
getMultipleSubjects

Subject
Subject
TrialDataQuery
TrialDataQuery

Subject
SubjectData
MultiSubjectData

d) Identify security patterns: The purpose of this task is to identify and select security
patterns that will ensure security requirements will be met. The output is an updated
Software Architecture Document.

There are three key security patterns for these services: 1) Identity and Authentication; 2)
Authorization; and 3) Message Protection. These patterns are required because of the
sensitive and personal nature of the information being handled.

e) Document service state-management decisions: This is a SOMA task that is not
included in the RUP/SOMA process description. The purpose of this task is to determine
if state information must be maintained across the invocation of composed services.

Subject will assigned various states (e.g., candidate or eligible) as part of executing
business processes. However, the state does not need to be maintained across composed
services. No other entities require state information.

2) Perform Subsystem Analysis: This activity is used to understand the relevant
subsystems within the business and map them to their IT counterparts. Table 18
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summarizes the tasks and their inputs and outputs.

Table 18. Perform Service Specification Tasks, Inputs, and Outputs.
Task
Inputs
Outputs
Subsystem design Business Analysis Model Design Model
Design Subsystem
Interface

a) Subsystem design (SOA): The purpose of this task is to link business models to their
counterparts. To do this, functional areas are mapped to subsystems. Then the
subsystem behaviors, internal structures, and dependencies are defined. The output is a
component-level Design Model.

The first step in this task is to use output from functional area analysis to identify the
supporting subsystems. In Table 19, functional areas of interest in this study are mapped
to existing subsystems. To implement the new capabilities introduced in this study, a
new functional area, Community, has been added. The new subsystems are based on the
business object being processed. Refer to Figure 17 for depictions of each subsystem.

Table 19. Design Model: Functional Area Analysis of Clinical Trials Function.
Domain
Clinical
Trials

Functional Area
Clinical
Researchers
Community

Subsystem
Patient
Registration
Patient
Advocate
Subject
TrialData
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Description
Provides patient-related functions.
Provides registration-related functions.
Provides functions to manage patient
advocates.
Provides functions to manage potential
trial subjects.
Provides functions to provide reports
about trial data.

The next step is to review the subsystems and to identify any dependencies among them.
A detailed description of each subsystem associated with CTS and the relationships
among them is provided in [18] and is not duplicated here. The dependencies associated
with the new subsystems are shown in Table 20.

Table 20. Design Model: Subsystem Dependencies.
Subsystem
Patient
Advocate
Subject

Trial Data

Depends On Description
none
n/a
Patient
Advocate
Patient

Register
Patient
Advocate
Subject

The Patient Advocate system is used to ensure that the user is
authorized to access a particular candidate’s information.
The Patient subsystem is used to enter information about a
patient into the CTMS and must be completed before a subject
can be referred to a trial.
The Register subsystem is used to register the subject.
The Patient Advocate system is used to ensure that the user is
authorized to access a particular candidate’s information.
The Subject system is used to ensure that the user is authorized
to access a particular candidate’s information.

The final step is to identify the service components, function components, and technical
components. A service that is assigned to a subsystem typically becomes a service
component. Functional components provide additional business functions to the service
component and are often type managers. Technical components provide functions that
typically cross business domains. Table 21 identifies these components.

Upon analysis of subsystem interdependencies, it was determined that additional
technical components are needed to provide function to respond to inquiries about the
status of a patient advocate or subject. Confirm Subject Status and Confirm Patient
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Advocate Status have been added as technical components.

Table 21. Design Model: Component Identification.
Services

Service Component
Patient
Advocate

Recruit
Patient
Advocate
Register
Patient
Advocate
Manage
Trial
Candidate
Obtain Trial
Data

Functional
Component

Subject Trial
Data

Technical Component
Confirm
Patient
Advocate
Status

Confirm Obtain
Subject Trial
Status
Data

x

x

x

x

x

x

x

3) Perform Component Specification: This activity is used to specify more details about
the service components. Table 22 summarizes the tasks and their inputs and outputs.

Table 22. Perform Service Specification Tasks, Inputs, and Outputs.
Task
Component
specification

Inputs
Design Subsystem
Service Component (Design
Model)

Outputs
Service Component (Design
Model)

a) Component specification (SOA): The purpose of this task is to elaborate on the
service component design. This elaboration includes:
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•

Modeling the component flows. This is typically a Universal Markup Language
(UML) sequence diagram. However, for this study, component flows are
represented using Petri nets. The same Petri net can be used for Recruit Patient
Advocate and Manage Trial Candidate since both require create, read, update, and
delete (CRUD) processes, as shown in Figure 13. The Petri net for Register
Patient Advocate is shown in Figure 14. Diagram annotations are in Table 23 and
Table 24.

These Petri nets were developed and validated using Platform Independent Petri
net Editor 2.4 (PIPE2) [43].

Figure 13. Design Model: Petri net for CRUD.
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Table 23. Annotations for Recruit Patient Advocate and Manage Trial Candidate.
Place /
Transition
P0
P1
P2
P3
P4
P5
P6
P7
P8
P9
T0
T1
T2
T3
T4
T5
T6
T7
T8
T9
T10

Interpretation Description
User
Web Page
Data
User
Web Page
Database
Data
Data
Data
Data
Task
Task
Task
Task
Task
Task
Task
Task
Task
Task
Task

Not logged in
Application logon page; web server is available
List of authorized users
Logged in
Patient Advocates or Trial Candidates page (home page)
Connection to Advocates or Candidates database
Added database entry
Retrieved database entry
Updated database entry
Deleted database entry
Log in user
Display home page
Obtain database thread; add a patient advocate or trial candidate
Release database thread; display home page
Obtain database thread; retrieve database entry for patient
advocate or trial candidate
Release database thread; display home page
Update database entry
Release database thread; display home page
Delete database entry
Release database thread; display home page
Log out user

Figure 14. Design Model: Petri net for Register Patient Advocate.
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Table 24. Annotations for Register Patient Advocate.
Place /
Transition
P0
P1
P2
P3
P4
P5
P6
P7
P8
P9
T0
T1
T2
T3
T4
T5
T6
T7

•

Interpretation Description
User
Web Page
Data
User
Web Page
Database
Data
Database
Data
Data
Task
Task
Task
Task
Task
Task
Task
Task

Not logged in
Application logon page (web server is available)
List of authorized users
Logged in
Patient Advocates page
Connection to Advocates database
Retrieved database entry
Connection to Trials database
Registered patient advocate
Dropped patient advocate
Log in user
Display Patient Advocates page (home page)
Obtain Advocates database thread; retrieve database entry for
patient advocate
Obtain Trials database thread; register patient advocate to trial
Release database threads; display home page
Obtain Trials database thread; drop patient advocate from trial
Release database threads; display home page
Log out user

Identifying events and messages. A high level specification was provided in the
Service Model. The specification of events and messages is part of normal design
activity for web services and is not unique to SOMA so this task is not covered in
this study.

•

Specifying component attributes. This includes: 1) component properties and
attributes; 2) rules; 3) variations; 4) dependencies on other components; 5) any
composition of functional or technical components; 6) a list of the services
provided; and 7) a list of the services required. The attributes that are unique to
SOMA have been addressed in previous steps. Refinement is not unique to
SOMA, so this task is not covered in this study.
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•

Creating a component class diagram that shows the relationships between the
functional and technical components of each service component. This will be
used to conduct variability analysis. Component models are created to depict the
relationships among the components. Figure 15 shows the relationship between
ManageTrialCandidate and ConfirmPatientAdvocateStatus.

Figure 15. Design Model: relationship of components in Subject subsystem.

•

Allocating components to layers. The service components have been allocated to
`the Service Component layer, as illustrated in Figure 16.
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Figure 16. Design Model: architectural layers.

C. Service Realization.
This is the third phase of RUP/SOMA. During this phase, the Service Model is updated
to document realization decisions; and a proof-of-concept is conducted. Service
Realization consists of one activity, Realization Decisions.

1) Realization Decisions: This activity is used to evaluate various options to determine
how a service will be built. Table 25 summarizes the tasks and their inputs and outputs.
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Table 25. Realization Decisions Tasks, Inputs, and Outputs.
Task
Document service realization
decisions

Component specification

Construct architectural proof-ofconcept
Assess viability of architectural
proof-of-concept

Inputs
Reference Architecture
Service Model
Software Architecture
Document
Design Subsystem
Service Component
(Design Model)
Service Model

Outputs
Design Model

Architectural Proof-ofConcept
Business Case
Glossary
Risk List
Vision

Reference Architecture
Review Record

Service Component
(Design Model)

a) Document service realization decisions: The purpose of this task is to determine a
sourcing approach. The output is a Design Model.

RUP/SOMA describes a number of options for how to realize a service. They include:
1) developing the service in-house; 2) purchasing code for the service so it can be hosted
internally; 3) extracting and transforming functionality from an existing code source; 4)
subscribing to an existing publish-subscribe service; 5) creating a wrapper around legacy
code; or 6) using a web service offered by an outside business. The decisions for the
Community enterprise component are documented in Table 26. In all cases, the decision
to build in-house was due to lack of awareness of an existing service or source code. The
Patient and Registration services are realized through web services offered by a third
party.
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Table 26. Service Model: Service Realization Decisions.
Enterprise
Component
Community

Realized
Service
Subject
Patient
Advocate
Trial Data

Functional & Technical
Components
ManageTrialCandidate
ConfirmSubjectStatus
RecruitPatientAdvocate
RegisterPatientAdvocate
ConfirmPatientAdvocateStatus
ObtainTrialData

Realization
Decision
Build in-house
Build in-house
Build in-house
Build in-house
Build in-house
Build in-house

b) Component specification (SOA): The purpose of this task is to allocate components
to layers. This is a reiteration of the step performed during Service Specification. No
update is required.

c) Construct architectural proof-of-concept: This is a reiteration of the step performed
during Service Identification. During this phase, additional details about the services
may reveal additional issues to consider.

The proof-of-concept is focused on the high risk areas of the architecture. In this study,
the proposal to use third-party services brings significant risks, such as loss of service,
data loss, performance problems, unreliability of service, lack of interoperability, and
format changes [44]. Because of this, the proof-of-concept will be a working prototype
designed to demonstrate the feasibility of using caBIG Integration Hub to access the
Patient service. The goal of the prototype is to use the Patient service to enroll a patient
that has been defined in a separate application [45].
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d) Assess viability of architectural proof-of-concept: The purpose of this task is to
define how an Architectural Proof-of-Concept will be evaluated against Architectural
Requirements and Risks. Evaluation criteria are determined based on requirements that
are significant from an architectural perspective. The evaluation results are reviewed to
determine if these requirements can be met. If not, the project team may want to reevaluate the requirement priorities.

As indicated earlier, the highest risk aspects of the architecture are associated with use of
third-party services. Evaluation criteria involve the answers to these questions:
•

Can authentication and authorization be implemented to ensure secure access to
information?

•

Do the services provide the capability necessary to implement the complete
solution?

•

Will the performance characteristics allow the solution to scale?

•

Are the called services sufficiently stable from a capability, interface, and quality
perspective?

85

VIII Evaluation of Proposed Solution

After the Service Model and Design Model are created and technically validated via an
architectural proof-of-concept, it is appropriate to evaluate the proposed solution against
the original project goals, requirements, and expected benefits.

Figure 17 shows the overall architecture of the proposed solution. It includes service
components, web application components, and the relationships among the components.
Refer to Appendix I for a model of the Monitor Subject application using a Petri net.

Figure 17. Solution architecture.
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A. Evaluation Against Goals.
Because SOMA includes the Goal-Service Modeling step, there is a clear relationship
between business goals and the services being proposed, as shown in Table 27. As the
metrics identified in Table 16 are collected and analyzed, there will be objective evidence
to show that these services are effective in meeting business goals.

Table 27. Goal-Service Summary.
Goal or Sub-Goal
1: Reduce clinical trial costs.
1.1: Improve trial subject recruitment rates.

Services

1.1.1: Increase trust between clinical researchers and the
communities where they operate.
1.2: Improve trial subject retention rates.
1.2.1: Increase trust between clinical researchers and the
communities where they operate.
2: Improve quality of trial data.
2.1: Improve quality of data submitted by trial subjects.
2.1.1: Increase trust between clinical researchers and the
communities where they operate.
3: Receive effective treatment for a health concern.

Manage Trial Candidate
Confirm Subject Status
Recruit Patient Advocate
Register Patient Advocate
Confirm Patient Advocate Status
Obtain Trial Data
Obtain Trial Data

Recruit Patient Advocate
Register Patient Advocate
Obtain Trial Data
Recruit Patient Advocate
Register Patient Advocate
Manage Trial Candidate
Obtain Trial Data

B. Evaluation Against Requirements.
Some of the business requirements identified in Section VI will be addressed through
implementation of business processes that do not require an IT solution. Table 28 shows
the mapping between the business requirements and the new services that are part of the
solution. Note that the design and architecture meet requirement A-13, even though there
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is no specific service associated with it.

Table 28. Business Requirements Mapped to Services.
Business Requirement
A-1. Increase
awareness
A-2. Educate
physicians
A-3. Incorporate
community perspective

A-4. Provide culturally
appropriate education
A-5. Provide culturally
appropriate informed
consent
A-6. Incorporate
community needs and
priorities

A-7. Include members
of the community in
all stages of the
clinical trials process
A-8. Engage and train
research advocates

A-9. Engage
community physicians
and healthcare
providers

Business
Process
Perform
Outreach
Perform
Outreach
All existing
business
processes,
where
appropriate
Perform
Outreach
All informed
consent
processes
All existing
business
processes,
where
appropriate
All existing
business
processes,
where
appropriate
Manage Patient
Advocates
Refer Patient
Advocate
Refer Subject

All existing
business
processes,
where
appropriate

New Business
Use Case
none

n/a

none

n/a

none

n/a

none

n/a

none

n/a

none

n/a

none

n/a

Recruit Patient
Advocate
Train Patient
Advocate
Manage Trial
Candidate
Request Subject
Referral
Manage Referral
Request
none

RecruitPatientAdvocate
RegisterPatientAdvocate
ManageTrialCandidate
ConfirmPatientAdvocateStatus
ConfirmSubjectStatus
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Service

n/a

A-10. Ensure followthrough on
commitments to trial
subjects
A-11. Ensure ongoing
one-on-one
communication

A-12. Provide health
education to trial
subjects
A-13. Provide a single,
consistent interface
A-14. Disseminate
project outcomes

not applicable

none

n/a

Monitor Study

Monitor
Subject
Monitor Trial
Data
Obtain Trial
Data
none

ObtainTrialData

not applicable

none

n/a

Disseminate
Trial Results

Disseminate
Trial
Results
Obtain Trial Data

ObtainTrialData

Provide Health
Education

n/a

In addition to business requirements, some architectural requirements were identified in
Section V.C:
•

Requirement: The solution must be integrated with existing systems.
Assessment: This is largely possible because CTS is services-based. If different
systems had been chosen as the basis for this study, it might have been more
difficult to achieve integration.

•

Requirement: The system must accommodate multiple CTMS and CDMS backends.
Assessment: Because CTMSs and CDMSs are accessed via services, the
architecture is not limited to specific back-end systems. However, there may be
limitations based on the ability to create a service wrapper around a system.
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•

Requirement: The solution must be sufficiently flexible to accommodate the
specific requirements of each supported clinical trial.
Assessment: Because reusable services will be created and made public, solution
developers can mix and match them to accommodate their specific needs. It is
easier for them to fill in the missing functionality because the services have welldefined interfaces.

•

Requirement: The solution must support rapid deployment and be cost-effective.
Assessment: The expectation is that there will be less need to build functionality
from scratch. Solution developers should be able to spend less time implementing
core capabilities to support their trust-building activities so they can focus on
issues that are unique to a particular trial, such as translation of user interfaces.

C. Evaluation Against the Case Study.
As stated in Section III, trust in the Hispanic community is influenced by common
cultural characteristics. Table 29 shows the linkage between these cultural characteristics
and business processes or services.

In support of the case study, patient advocates recruited from the San Jose Hispanic
community would be managed using Recruit Patient Advocate and Register Patient
Advocate. This would include family members, community-based healthcare providers,
or primary care physicians.
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Table 29. Linkage between Trust Issues and Services.
Characteristic
Language
Family

Respect
Personal Relationships

Business Process Support
Develop Informed Consent Form
Obtain Informed Consent
Perform Outreach
Manage Patient Advocates
Disseminate Trial Results
Monitor Study
Disseminate Trial Results
Refer Subject
Monitor Study

Supporting Service Support
none
Recruit Patient Advocate
Register Patient Advocate
Obtain Trial Data
Obtain Trial Data
Manage Trial Candidate
Obtain Trial Data

Healthcare providers would be trained about the benefits of participating in clinical trials
and encouraged to refer patients using Manage Trial Candidate. Because the eligibility
requirements of the case study can be stated as rules that can be verified electronically, a
custom-built service to automatically verify eligibility could be developed and
incorporated into the solution. Because the solution is an SOA, incorporating this change
should be straight-forward.

Once the trial started, the trial subject would be able to view all trial data collected to date
and perhaps view trend data, such as changes in BMI over time, using Obtain Trial Data.
The subject’s healthcare provider would also be able to use the service to view the
patient’s progress and, perhaps, to order lab tests to monitor the effects of better diet and
improved BMI on other health indicators, such as blood sugar, cholesterol levels, and
blood pressure.
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D. Summary.
Table 30 contains a summary of the evaluation. The primary business goals can be met if
trust is improved through use of the proposed solution. Most of the architectural
requirements have been realized. Linkages between these services and increased trust in
the San Jose Hispanic community were demonstrated.

Table 30. Summary of Solution Evaluation.
Project Goal Requirement
Goal
1. Reduce clinical trial costs.
2. Improve quality of trial data.
3. Receive effective treatment for a health concern.
Requirement
The solution must be integrated with existing systems.
The solution must be sufficiently flexible to accommodate
the specific requirements of each supported clinical trial.
The solution must support rapid deployment and be costeffective.
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Goal Met or Requirement Met
Yes, due to improved trust
Yes, due to improved trust
Will depend on effectiveness of
treatments under study
Yes
Yes
Too early to determine

IX Summary and Conclusions

The technical solution conceived at the beginning of this study to address trust-building
between clinical researchers and the San Jose Hispanic community was fairly
straightforward. The intent was to design a services-based application that would: 1)
manage a database of potential trial subjects, healthcare providers, and patient advocates;
2) give trial subjects and their primary healthcare providers access to trial data; and 3)
provide a means for community members and clinical researchers to interact with each
other.

As a stand-alone application for a single trial, this would have been simple and quick to
implement. However, that would have been a short-sighted solution. There might be
duplicate or overlapping efforts by different IT staff; the community might experience a
lack of continuity from trial to trial due to lack of data sharing; or relationships
established during one trial might have to be rebuilt in the next. Managing each clinical
trial in the community differently would not encourage trust.

A better approach was to find a way to implement a solution that could provide a
consistent interface to the community while accommodating the various CTMSs used by
different researchers. An SOA approach was explored using the RUP/SOMA
methodology.
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Because RUP/SOMA assumes that requirements analysis has been completed, a
methodology was developed to translate non-functional wants and needs to technical
requirements. The resulting requirements specification became input to the RUP/SOMA
methodology.

RUP/SOMA focuses on the architecture and design of external web services, using
SOMA notations and Unified Modeling Language (UML) to model them.
Petri nets were used to simulate flows among web services and validate the architecture.

The solution was evaluated against the original business goals and requirements. The
methodology for deriving the requirements provided linkage from the non-functional
wants and needs to business processes to technical requirements. RUP/SOMA provided
linkage from the business goals to service components. Because these two
methodologies maintained traceability throughout the definition of the architecture, the
result addressed all goals and requirements.

A. Next Steps.
The next steps for this study are to plan and execute the architectural proof-of-concept.
The functional requirements and use case for the proof-of-concept have been defined
[45]. Initial investigation of the service messages associated with Patient and the
protocols for using Integration Hub has been completed. Additional details must be
added to the component specification, to provide greater details about how to invoke the
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Patient service and deal with any errors from the service.

A number of issues arose that require consideration: First, the services being provided by
caBIG are being defined and prototyped concurrently with this study. Because of this,
service capabilities, interfaces, and protocols have been subject to change. Second, to
test this system, the entire caBIG infrastructure, including caGRID, must be installed.
Further work on the proof-of-concept should be delayed until the required third-party
services are implemented and stable and a test harness is in place.

After completion of the proof-of-concept, implementation, deployment, and management
should follow. The solution should be re-evaluated at key checkpoints during the service
life cycle to ensure it continues to meet original intents.

It should be noted that the methodology defined in Section VI is not domain-specific so it
may be sufficiently general and complete to be used for transforming any non-functional
requirements into implementable technical requirements. Further work is needed to
confirm this.

B. Recommendations.
This paper concludes with some observations about the RUP/SOMA methodology, along
with recommendations for projects contemplating its use.
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1) Project Selection: If a project is small and limited in scope, the additional effort
expended to follow the RUP/SOMA methodology may not yield any measurable benefit.
The SOA governance process should have criteria for determining which projects are in
the scope of the SOA and which are not. This lets the enterprise focus resources and
efforts on the solutions most likely to yield high-value services.

This study also demonstrated that use of the RUP/SOMA methodology does not have to
be restricted to an individual business. It can also be used to architect a solution for a
well-defined business process that is shared by an industry.

2) Consideration for the Existing IT Environment: RUP/SOMA can be used to architect
services in both SOA and non-SOA environments. However, it is a much more difficult
task to use the methodology if the enterprise has not already adopted some kind of formal
IT architecture or if it has not documented an inventory of its software.

The operation-first approach suggests a comprehensive search for reuse opportunities
throughout the entire enterprise. This can be very time-consuming in an environment
where needed information is not available. When architecting a relatively small solution
of limited scope such as the trust-building application, starting the service identification
at the sub-function level may be more cost-effective, as the opportunities for reuse are
more likely within that sub-function or the immediate function enclosing it.
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3) Business Goals: RUP/SOMA focuses on business goals; but many times the effect a
small project has on the top business goals can be minimal. When performing goalservice modeling, it is important to start with goals at an appropriate level within the
business where the positive impacts of the services can actually be discerned.

4) RUP/SOMA and the Software Development Life Cycle: To perform service
identification adequately, the software architect must have a clear understanding of the
requirements and some idea of how those requirements will be met from a functional
perspective. Also, during the services realization phase, the decisions there can
significantly impact the software development schedules, test plans, and resource
allocations.

To be effective, the RUP/SOMA methodology must be tightly integrated with the normal
software development life cycle (SDLC) so external services design and architecture are
performed in parallel with activities for the other components of the project. Buy-versusmake decisions should be made as early as possible to enable better project planning.

5) SOA Metrics: Even though a service is perfectly aligned with business goals, its
maintenance and upkeep as a service may not be cost-effective if that service has only a
few internal consumers. Metrics should be identified to measure the effectiveness of
service selection as part of SOA governance.
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6) SOA Governance: During the service identification phase of RUP/SOMA, the
mapping from business processes, as understood by the business process analyst, to
services, as understood by the software architect, is performed. To ensure the mapping
across these two disciplines is correct, it is highly recommended that SOA governance
include policies regarding model reviews and approvals. Similarly, goal-service models
should be reviewed by a cross-functional team.

All models should be retained and be accessible for use by other projects in the enterprise
to minimize duplicate efforts. These models should be reviewed periodically to ensure
they still reflect current business goals and practices.

In conclusion, even though the RUP/SOMA methodology focuses on an enterprise-wide
SOA, it is possible to use the methodology within a single business function or subfunction as the starting point for an SOA. By narrowing the scope, the architect can
identify reusable components in a more cost-effective way. Other strategies for success
are tighter integration with the SDLC, identification of metrics to measure the
effectiveness of service selection, and model review.
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Appendix A Sample Questions to Elicit Domain Solutions

Prior to architecting a solution, it is important to understand what the solution
requirements are. One way to determine solution requirements is by interviewing clinical
trial participants to understand the underlying causes for lack of trust. Figure 18, Figure
19, Figure 20, and Figure 21 are samples of questions an architect can ask to get a better
understanding of the requirements. For this study, solution requirements were
determined by [4]-[9], [11], [12].

Questions for Clinical Researchers
1. Research history
a. Have you conducted any clinical research targeted at the Hispanic community within
the last 5 years? If no, skip to 1c.
b. What was the purpose of the most recent one? Skip to 2.
c. Have you conducted any clinical research within the last 5 years that may have
included members of the Hispanic community? If no, skip to 8.
d. What was the purpose of the most recent one?
These questions are for the most recent study.
2. Participants - data
a. How many participants did you plan to include in the study?
b. How did you go about finding participants? (Examples: advertising in papers, direct
mail, through community clinics)
c. Was any study information translated in Spanish? If so, what?
d. What was the actual number of participants?
e. What tools did you use to manage recruitment? Patient data? Were you satisfied with
them? Why/why not?
3. Participants - observations
a. What techniques were most successful in recruiting participants?
b. Were there any issues associated with informed consent?
c. Are there any things you would do differently in the recruitment process?
d. What techniques or tools, if any, would improve your recruiting process?
4. Managing participation - data
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5.

6.

7.

8.

a. How long was each participant expected to participate?
b. What were participants required to do?
c. How were study requirements communicated to each participant? Were they in
Spanish?
d. How did you monitor patient participation?
e. How often did you contact them directly?
f. If a participant had questions or concerns, how did they contact you?
g. What tools did you use to manage participation? Patient data? Were you satisfied with
them? Why/why not?
Managing participation – observations
a. Were you satisfied with the quality of input from participants? Why/why not?
b. Are there any actions you would recommend for improving the quality of input in
future studies?
c. What techniques or tools, if any, would help you manage participation better?
d. What would help you manage patient data better?
Interaction with primary care physicians
a. Were participants’ primary care physicians informed of their participation in the study?
If so, how?
b. Was there a way for physician to communicate directly with the researchers during the
study? If so, how?
c. Was participant data made available to physicians during the study? If so, how?
d. Do you think greater involvement by patient primary care physicians would have
resulted in better participation or higher quality results?
e. If primary care physicians involved: What tools did you use to communicate with
physicians? Were you satisfied with them? Why/why not?
Interaction with community leaders
a. Were any community leaders involved in your study? If yes, what was their role?
b. How did you communicate with them?
c. What tools did you use? Were you satisfied with them? Why/why not?
Thank researcher for his/her time.

Figure 18. Sample questions for clinical researchers.

Questions for Community Leaders
1. Local issues and concerns
a. What are the most important health issues in the Hispanic community?
2. Encouraging participation in clinical research
a. Do you think it’s important for the local Hispanic community to participate in clinical
research focused on these issues? Why or why not?
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b. Are you aware of any clinical research in the last 5 years that has been focused on
these issues?
c. If yes, how did you hear about it?
d. If yes, did you actively promote participation in that research? Why or why not? If yes,
how?
3. Engaging leaders
a. Were you included in the planning of the study? If so, how?
b. Were you kept informed of progress? If so, how?
c. How important was it to you to be included in study planning and execution?
d. What information would be most useful to you?

Figure 19. Sample questions for community leaders.

Questions for Healthcare Professionals
1. Encouraging participation in clinical research
a. Are you aware of any clinical research in the last 5 years that would be beneficial to
your Hispanic patients?
b. If yes, how did you hear about it?
c. If yes, did you actively promote participation in that research? Why or why not? If yes,
how?
2. Engaging healthcare professionals
a. Were you included in the planning of the study? If so, how?
b. Were you kept informed of progress? If so, how?
c. How important was it to you to be included in study planning and execution?
d. What information would be most useful to you?

Figure 20. Sample questions for healthcare professionals.

Questions for Participants
(To ensure privacy, will not ask about the specifics of the study; focus on the process.)
1. Informed consent
a. How was the purpose of the study and the risks explained to you?
b. Did you feel the researchers communicated this clearly to you?
2. Study process
a. How did researchers explain what was required from you?
b. How did you communicate with researchers during the study? How often?
c. If you had questions or concerns during the study, how could you contact a researcher?
Did you have to do that during the study? If so, were you happy with the
answer/resolution?
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d. Did you participate for the full planned period? If not, why not?
3. Follow-up
a. When did your participation in the study end?
b. Did researchers contact you any time after the end of your participation? If so, why? If
not, would you want them do?
c. Were you informed of the overall results of the study? If so, how?
4. Satisfaction
a. Were you satisfied with your communications with researchers?
b. If you had the opportunity to participate in another study, would you? Why/why not?
c. Would you personally recommend participation to others? If not, why not?

Figure 21. Sample questions for participants.
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Appendix B General Trust-Building Model

Merriam-Webster Online Dictionary defines trustworthiness as “worthy of confidence”
[46]. Lewicki and Tomlinson [47] further assert that assessment of an individual’s
trustworthiness is based on three dimensions of trustworthy behavior. These dimensions
are ability, integrity, and benevolence. The more an individual exhibits these behaviors,
the more that person is deemed trustworthy. Evaluation is based on questions such as: Is
this individual competent? Based on past actions, is this individual truthful, does the
individual follow through on commitments, and has the individual acted fairly? Is this
individual concerned about my welfare?

Although these dimensions were defined for individual trustworthiness, they were used as
part of this study to evaluate whether or not the solutions proposed in Section II could
improve trustworthiness of researchers from the perspective of members of the San Jose
Hispanic community. Figure 22 maps the problem themes identified in Section II to the
trust dimensions defined by Lewicki and Tomlinson [47]. The problem themes that
cannot be mapped directly to one of the trust dimensions are aspects that influence an
individual’s assessment of trustworthiness. This is illustrated in the upper left corner of
Figure 22.

Based on this mapping, this study concludes that a solution addressing these problem
themes will increase community trust in clinical research and will positively impact a
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community’s assessment of clinical research trustworthiness.

Figure 22. Mapping problem themes to dimensions of trust.
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Appendix C Final Report Summary from NIH Roadmap Projects

Table 31 summarizes the information technology aspects of the NIH projects and impacts, if any, on underserved communities.

Table 31. Summary of Broad Agency Announcement (BAA) Report.
Researcher

Information Technology

Features

Technologies Used

MCRC
Univ of
Michigan

Honest Broker

Registry
Messaging
Data transformation and
filtering
Security and privacy
Administrative control
Networking capability for
data exchange
Platform-independent
messaging system

International standardsbased protocol stack for
biomedical data
encoding
3-tier
Java
P2P with authorized
external applications
Data dictionary
containing Common
Data Elements (CDEs)
Java
Globus security model
Grouper group
management
Open source
applications
TB data standards
Web service evaluated
but not used due to cost

ClinfoTracker
AGNIS
National
Marrow Donor
Program

AGNIS

TB Trials
Network
Duke Univ Med
Center

Query Tracking System

Query identification and
tracking

AE/SAE Tracking

Reporting
Trial management
Forum for team member
collaboration

Web portal
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Impacts of research on
community interactions and
reaching underserved populations
Delivery of enriched clinical data
to the PCP; extensions to the
prompt and reminder system

No direct interaction with patients
or underserved populations

Not available

ALCHEMIST
CTN Best
Practices
Med Center

CTN Best Practices web site
www.ctnbestpractices.org

Clinical Trial Management
System (CTMS)

Investigator Profile Library

Data Standards Inventory

InterTrial
Columbia Univ

WorkWeb

CNICS
UCSF

FASTA

HL7-HLC

MIRTH
Website tools

Data Entry tool for nonelectronic phenotypic data
Data analysis tools

CRN Harmony

Clinical Research

Decision analysis model
(economic)
Resources related to
institutional review boards,
clinical sites new to research,
regulatory requirements, etc.
Manage information about a
clinical research study,
including individuals and
organizations
Repository of information on
clinical site investigators and
staff
Identifies organizations
creating or promoting
standards
Project management
Individuals connected
through various relationships
to other entities
Data transfer system deidentifies, reformats, and
aggregates
Translates HL7 data to
format required by CNICS
sites
Translates HL7 to XML
For importing, validating,
and posting data on public
website
Consistent and reliable
structure for manual entry
Interpret HIV treatment
choices and medication
categories
Supports clinical and
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Acute Coronary
Syndrome (ACS) data
standards
Open source

Not available

Wiki and other social
software

Sites for this study were chosen
due to existing good relationships
with local communities
Not applicable

Oracle Clinical

Re-use of common data elements

Univ of
Pennsylvania

Informatics Platform

translational research
products

Pharmaceutical
Application (OPA)

HMORN CCSN Virtual Data Warehouse
Group Health
Cooperative

Stores laboratory data

Critical Care
Decisions
LDS Hospital
ePCRN
Univ of
Minnesota

eProtocol-insulin

Protocol to calculate changes
in IV insulin drip rate

ePCRN Gateway

Registration of clinical
Standardized multiplepractices
disease registry
Security
Globus Server
Locally controlled filters
Imports Continuity of Care
Record XML strings (CCR)
Local identification of
patients matching eligibility
criteria
Print, email, text messaging
Specific disease management
software
Single access site for queries
CDEs for pediatric
blood and marrow
transplantation

COG
Children’s
Oncology
Group
RIOS Net
University of
New Mexico

ePCRN Research Portals
None specified

RIOS Net IT infrastructure

Centralized data and
processes
Data collection: web,
commercial software,
scanned, PDAs
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SQL Server

in collecting study elements
enables researchers to consider
characteristics of the underserved
Greater interest and willingness to
participate in clinical research by
selected cardiologists with access
to program
PRISM readability toolkit makes
content more accessible
Not available

ePCRN is suited for involvement
of practices located in
underserved areas
Promotes better communication
and collaboration at remote sites
Being considered at Hispanic
clinics in Los Angeles.

Enhanced ability to perform pilots

All research is centered on
underserved populations.
Community outreach staff
expanded communications into
these communities.

Appendix D Mapping between SOMA and RUP/SOMA

Table 32 identifies the differences between SOMA and RUP/SOMA [36], [48]. Both
methodologies consist of three major steps: 1) identification; 2) specification; and 3)
realization. Each step is further decomposed into activities, shown in the SOMA Activity
column. In the SOMA Task column, the specific tasks to be completed for an activity as
defined by SOMA are listed. In the RUP/SOMA Content column, the equivalent task or
guideline is identified.

Table 32. Mapping between SOMA and RUP/SOMA.
SOMA Activity
SOMA Task
Service Identification
Domain
Functional Area Analysis
Decomposition
Process Decomposition
Variation-Oriented Analysis
Goal-Service
Identify Goals and Sub-goals
Modeling
Identify Services for Sub-goals

Existing Asset
Analysis

Identify KPIs and Metrics for Subgoals and Services
Existing Asset Analysis

Service Specification
Service
Apply Service Litmus Tests
Specification
Model Service Dependencies
Model Service Composition and
Flow
Document Service Non-Functional
Requirements
Specify Service Messages

Subsystem Analysis

Document State Management
Decisions
Identify Subsystem Dependencies
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RUP/SOMA Content
Functional Area Analysis
Refine a Business Use-Case
Variability Analysis
Identify Business Goals and
KPIs
Identify and Associate Services
to Goals
Identify Business Goals and
KPIs
Existing Asset Analysis
Data Model Analysis
Business Rule Analysis
Apply Services Litmus Tests
Service Specification

Service Specification
Message Design
Service Specification
Subsystem Design (SOA)

Component
Specification

Identify Service Component
Identify Functional Components
Identify Technical Components
Specify Component Attributes
Identify Events and Messages
Model Component Internal Flow
Create Component Class Diagram
Variation-Oriented Design

Service Realization
Realization
Decisions
Service Allocation
Component Allocation to Layers
Technical Feasibility Exploration
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Component Specification (SOA)

Variability Analysis
Document Service Realization
Decisions
Component Specification (SOA)
Construct Architectural Proofof-Concept (SOA)

Appendix E Service Model and Design Model

The Service Model is updated throughout all phases of the RUP/SOMA methodology,
and the Design Model is updated during the Specification phase. Table 33 and Table 34
contain outlines of the two models and provide indexes to sections in the main document
where content has been defined.

Table 33. Index to Service Model Content.
RUP/SOMA Step Where
Created
Identification
Specification

Realization

Service Model Section

Table or Figure

Service Portfolio
Service Hierarchy
Service Exposure
Service Dependencies
Service Composition & Flow
Service Messages
Service Non-Functional
Requirements
State Management Decisions
Realization Decisions

Table 15
Figure 8
Table 14
Figure 12
n/a
Table 17
n/a

Table 26

Table 34. Index to Design Model Content.
RUP/SOMA Step Where Created
Specification

Service Model Section
Functional Area Analysis
Subsystem Dependencies
Component Identification
Component Internal Flow
Component Class Diagrams
Allocation to Architecture Layers
Events and Messages
Component Attributes
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Table or Figure
Table 19
Table 20
Table 21
Figure 13, Figure 14
Figure 15
Figure 16
n/a

Appendix F Business Process Flows

Implementing RUP/SOMA requires understanding of the business process flows. Figure
23 shows the as-is business process flow for the clinical trials process, and Figure 24
shows the to-be business process flow. Manage Community is a new process that
includes sub-processes to manage activities associated with members of the community.
A decomposition of Manage Community business process flows is shown in Figure 25.

Figure 23. As-is clinical trials business process.
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Figure 24. To-be clinical trials process.

Figure 25. Decomposition of Manage Community.
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Appendix G Business Actors and Business Use Case Model

To identify an appropriate set of use Business Actors and Business Use Cases to review
for refinement, an earlier version of the SOMA methodology was used [34]. In that
version of SOMA, two business process models are developed. The as-is model
describes the current business; and to-be model describes the desired future business. A
comparison of the two models yields the business use cases that will require review.

A. As-Is Business Use Case Model.
caBIG created a business architecture model for clinical trials [37] that was used to
represent the as-is business use case model in this study. The business use case model is
represented using Unified Modeling Language (UML). Only that subset of use cases that
are relevant to trust-building activities will be shown.

caBIG identifies four categories of business use cases for Manage Clinical Research,
shown in Figure 26. These categories are a way of partitioning the use cases and are not
intended to represent the business processes.

Figure 26. Business use case categories for as-is Manage Clinical Research.
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The use cases for Plan Study, shown in Figure 27, represent preparatory activities
covering scientific aspects, logistics, regulatory and legal issues, and finance. This
includes activities such as identification of the study team, trial design, recruitment plans,
and trial monitoring.

Figure 27. Business use cases for as-is Plan Study.

The use cases for Initiate Study, shown in Figure 28, cover study activation activities.
This includes recording and maintaining participant information and training for trial
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personnel.

Figure 28. Business use cases for as-is Initiate Study.

Conduct Study contains a number of relevant use cases, including one to grant access to
data, several to manage trial subject registration, and others to manage trial subject
schedules. These are shown in Figure 29.

The Report and Analyze Study use cases focus on regulatory and scientific reports and
data. Sharing Data for Collaborative purposes focuses on ad hoc reporting, as shown in
Figure 30.
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Figure 29. Business use cases for as-is Conduct Study.

Figure 30. Business use cases for as-is Report and Analyze Study.

B. To-Be Business Use Case Model.
To determine which business uses cases require update and what new business use cases
may be required, the as-is use cases are mapped against business requirements. Table 35
shows the business requirements derived in Section VI mapped to appropriate as-is
business use cases.
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Table 35. Mapping Business Requirements to As-Is Business Use Cases.
Business Requirement
A-1. Increase awareness about
clinical research and the clinical
trials process through education,
outreach, and advocacy.
A-2. Educate physicians on the
benefits to their patients and to
themselves of participating in
clinical trials.
A-3. Incorporate a community
perspective in the clinical trials
process.
A-4. Build community awareness
of researcher presence; provide
clinical trials education that is
culturally appropriate.
A-5. Use culturally appropriate
questions and translations to
ensure comprehension and
accessibility of informed consent.

A-6. Incorporate community
needs, patient perspectives,
priorities, issues, and concerns in
trial design.

A-7. Include members of the
community in all stages of the
clinical trials process for input,
monitoring, and decision-making.
This includes participation on
review boards and on data safety
monitoring boards.

A-8. Engage and train research
advocates to participate in all
stages of the clinical trials process,

As-Is Business Use
Case
none

Use Case
Category
none

none

none

none

none

none

none

Develop Informed
Consent Form
Conduct StudySpecific Personnel
Training

Plan
Study
Initiate
Study

Determine Logistical
Feasibility of
Study/Trial
Completion
Determine Patient
Care Funding

Plan
Study

Define Objectives

Plan
Study
Plan
Study
Plan
Study
Plan
Study
Plan
Study
Plan
Study
none

Develop Eligibility
Criteria
Define Ancillary
Studies
Describe Study
Design and Schema
Develop Accrual
Plan
Describe Patient
Recruitment Plan
none
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Plan
Study

To-Be Updates
Add category:
Manage Pre-Study
Add use case:
Perform Outreach
See A-1.

Incorporated in
other business use
cases
See A-1.

none
Add actor: Patient
Advocate to provide
input to training and
optionally to provide
training
Add actor: Patient
Advocate to provide
input
Add actor: Patient
Advocate to provide
input
none
none
none
none
none
none
Add use case:
Manage Patient
Advocates to

including subject recruitment.

A-9. Engage community
physicians and healthcare
providers as study investigators or
by utilizing their facilities.

A-10. Ensure follow-through on
commitments to trial subjects.
A-11. Ensure ongoing one-on-one
communication with trial
participants throughout the trial
and be responsive to concerns.

none

Initiate
Study

none

Conduct
Study
Plan
Study

Define Professional
Qualifications of an
Investigator Needed
for Study Trial
Identify and Contact
Study/Trial Team

Plan
Study

Manage Pre-Study
Add use case:
Register Patient
Advocate
Add use case:
Refer Subject
none

Add step: Primary
Investigator includes
community
members on the
team as patient
advocates
Add step: Contact
physicians in the
community to elicit
input
not applicable

Identify Participating
Sites (Site
Identification)

Plan
Study

none

none

Develop Study
Specific Data and
Safety Monitoring
Plan
Develop Study
Specific Plan for the
Safety, Monitoring,
and Evaluation of
Participants
none

Plan
Study

none

Plan
Study

none

Conduct
Study

Report and Analyze
Study

Report
and
Analyze
Study
Conduct
Study

Add use cases:
Monitor Subject,
Monitor Trial Data
Add use case:
Obtain Trial Data

A-12. Provide health education to
trial subjects that is sensitive to
cultural values and beliefs.

none

A-13. Provide a single, consistent
interface between the community
and different researchers.

none

none
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Add use case:
Provide Health
Education
n/a

A-14. Disseminate project
outcomes.

none

none

Add category:
Manage Post-Study
Add use case:
Disseminate Trial
Results

The Business Requirement column contains the suggested actions identified previously;
the As-Is Use Case column identifies an existing use case that is relevant to the business
requirement; the Use Case Category column identifies the applicable category; and the
To-Be Updates column identifies the changes or additions to be made to use cases or to
use case categories.

Candidates for implementation via software systems are highlighted in bold. They are
Manage Patient Advocates, Refer Subject, Monitor Subject, Monitor Trial Data, Obtain
Trial Data, and Disseminate Trial Results. Perform Outreach is focused on general
awareness and is most likely the responsibility of functions such as marketing
communications, so it is outside the scope of the clinical trials process. Business use
cases associated with training, such as Provide Health Education, may be supported via
software systems, but will most likely be conducted in a face-to-face manner.

If the to-be update is specified as “none,” the as-is use case already addresses the
business requirement, usually through incorporation of a patient advocate in the process.
If the to-be update is specified as “not applicable,” the business requirement describes an
action that must be implemented through some means other than by a business process.
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In the following figures, new or modified business use cases are highlighted with bold
outline based on the mapping shown in Table 35. Figure 31 shows two new categories of
business use cases, Manage Pre-Study and Manage Post-Study. These business use cases
will describe activities to be conducted before or after a clinical trial. Preliminary
activities would include awareness activities and patient advocate and healthcare provider
recruitment and training. Follow-on activities would include disseminating trial results.

Figure 31. Business use cases for to-be Manage Clinical Research.

The Manage Pre-Study is a new classification of business use cases that will address
activities that are performed to establish trust prior to a study. Perform Outreach targets
media, policy makers, communities, and healthcare providers. Manage Patient
Advocates includes activities for maintaining relationships with patient advocates, such
as recruitment and training. These are shown in Figure 32.
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Figure 32. Business use cases for Manage Pre-Study.

No new use cases need to be created for Plan Study. In many cases, the as-is business
use case already included a patient advocate as one of the actors. Because the patient
advocates are there to represent the patient view, many of these business use cases may
already be capable of improving trust.

Some business use cases require some modification to include participation by patient
advocates or by physicians in the community. These are Determine Logistical Feasibility
of Study/Trial Completion, Determine Patient Care Funding, Identify and Contact
Study/Trial Team, and Identify Participating Sites (Site Identification). These business
use cases are further details of Develop Preliminary Scientific Plan, Develop Financial
Contractual Plan, Develop Preliminary Admin Plan, and Develop Admin Plan business
use cases, respectively, as shown in Figure 33.
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Figure 33. Business use cases for to-be Plan Study.

Register Patient Advocate is a new business use case in the Initiate Study category.
Patient advocates will need to be identified to the electronic systems since they will
require authorization to access trial data. Conduct Study-Specific Personnel Training
must be modified to include patient advocate input. A summary of additions and changes
are shown in Figure 34.
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Figure 34. Business use cases for to-be Initiate Study.

Four new business use cases need to be created for Conduct Study. They are Refer
Subject, Monitor Subject, Monitor Trial Data, and Provide Health Education. A fifth
business use case, Monitor Study has been created, as a convenience, to aggregate the
monitoring use cases. A summary of additions and changes are shown in Figure 35.

One new use case, Obtain Trial Data, needs to be created for Report and Analyze Study,
as shown in Figure 36. This use case will generate patient and trial views of data in
response to ad hoc requests from trial subjects and patient advocates and for general
reports to the community.
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Figure 35. Business use cases for to-be Conduct Study.

Figure 36. Business use cases for to-be Report and Analyze Study.

Manage Post-Study business use cases will address activities that are performed to
maintain community trust after a study has completed. Disseminate Trial Results targets
community members, such as community-based research partners, trial subjects and their
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physicians, patient advocates, and community leaders. This is shown in Figure 37.

Figure 37. Business use cases for Manage Pre-/Post-Study.
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Appendix H New Business Actors, Business Models, and Business Use Cases

Although not part of RUP/SOMA, the Service Identification task to refine a business use
case should be applied to new use cases. New business actors should be defined,
business models should be refined, and business use cases defined in sufficient detail to
be realized.

A. Business Actors.
Business use case analysis yielded new actors, Patient Advocate Coordinator,
Community Member, and Community Outreach Coordinator. Brief descriptions of each
actor are provided below:
•

The Patient Advocate Coordinator is responsible for recruiting, training, and
managing patient advocates and community healthcare providers.

•

A Community Member can be a community leader, a community-based
healthcare provider, community healthcare providers, or potential trial subjects
and their families.

•

The Community Outreach Coordinator is responsible for general outreach
activities to media, policy makers, community leaders and members, and
healthcare providers-in-training.

B. Business Model Refinement.
The business models for Manage Patient Advocates and Refer Subject have been further
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refined, as shown in Figure 38 and Figure 39.

Figure 38. Refinement of Manage Patient Advocates business use case.

Figure 39. Refinement of Refer Subject business use case.

C. Detailed Business Use Cases.
Details for each business use case to be implemented follow.
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UC0001: Recruit Patient Advocate
Participating Actors: Patient Advocate Coordinator
Description: Maintain contact information for a healthcare provider (e.g., enrolling physician) or
a patient advocate. Information can be added, changed, displayed, or deleted.
Preconditions:
1. User is authorized to perform read, create, update, and delete participants.
2. User has accessed the application logon page.
Postconditions: An entry for an advocate has been read, created, updated, or deleted.
Main Success Scenario
Actor
1 The user requests to log into the
system.

System

Resource

2 The system requests user
authorization / authentication.
3 Return authorization
/ authentication status.
4 The system displays the Patient
Advocates page showing a list of
processing options.
5 If the user chooses to add an
advocate
5.1 The system displays a form to
collect information.
5.2 The user enters the required
information and submits a request.
5.3 The system verifies that the form
fields contain valid data.
5.4 The system requests to create an
entry in the Advocates repository.
5.5 The database
creates an entry.
5.6 The system displays a message to
indicate the entry was created
successfully.
6 If the user chooses to review,
update, or delete
6.1 The system displays options to
process a single entry or multiple
entries.
6.2 If the user chooses to process
from a list of advocates from the
repository
6.2.1 The system requests to retrieve
all entries in the Advocates repository.
6.2.2 The database
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retrieves all entries.
6.2.3 The system displays the results,
sorted in alphabetical order by last
name.
6.2.4 The user selects one of
advocates to process and submits a
request to review, update or delete.
6.3 If the user chooses to process a
single entry
6.3.1 The system displays a form to
enter the name of the advocate.
6.3.2 The user updates the form and
submits a request to update or delete.
6.3.3 The system verifies that the form
fields contain valid data.
6.4 The system requests to retrieve the
entry in the Advocates repository for
the requested advocate.
6.4.1 The database
retrieves the entry.
6.4.2 The system displays the current
data for the advocate.
6.5 If the user chooses to change
information about an advocate
6.5.1 The user updates the form and
submits a request.
6.5.2 The system verifies that the form
fields contain valid data.
6.5.3 The system requests to update
the entry in the Advocates repository.
6.5.4 The database
updates the entry
6.5.5 The system displays a message to
indicate the entry was updated
successfully.
6.6 If the user chooses to delete an
advocate from the repository
6.6.1 If the user confirms delete
6.6.2 The system requests to delete the
entry from the Advocates repository.
6.6.3 The database
deletes the entry.
6.6.4 The system displays a message to
indicate the entry was deleted
successfully.
6.6.5 If the user cancels delete
7 The system displays the Patient
Advocates page.
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UC0002: Register Patient Advocate
Participating Actors: Patient Advocate Coordinator
Description: Assign a patient advocate to an active trial. Information can be added, changed,
displayed, or deleted.
Preconditions:
1. User is authorized to perform read, create, update, and delete participants.
2. User has accessed the application logon page.
Postconditions: Advocate has been added or dropped from a clinical trial.
Main Success Scenario
Actor
1 The user requests to log into
the system.

System

Resource

2 The system requests user authorization /
authentication.
3 Return authorization
/ authentication status.
4 The system displays the Patient Advocates
page with options to process a single entry or
multiple entries.
5 If the user chooses to process
from a list of advocates from
the repository
5.1 The system requests to retrieve all entries
in the Advocates repository.
5.2 The database
retrieves all entries.
5.3 The system displays the results, sorted in
alphabetical order by last name.
5.4 The user selects one of
advocates to process and
submits a request to register or
drop.
6 If the user chooses to process
a single entry
6.1 The system displays a form to enter the
name of the advocate.
6.2 The user updates the form
and submits a request to
register or drop.
6.3 The system verifies that the form fields
contain valid data.
7 The system requests to retrieve the entry in
the Advocates repository for the requested
advocate.
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8 The database
retrieves the entry.
9 If the request is to register, the system
requests to retrieve a list of active trials from
the Trials repository.
10 If the request is to drop, the system
requests to retrieve a list of trials associated
with the advocate from the Trials repository.
11 The database
retrieves the list.
12 The system displays the current data for
the advocate.
13 If the user chooses to
register the advocate for one or
more trials
13.1 The system requests to update the entry
in the Advocates repository.
13.2 The database
updates the entry
13.3 The system displays a message to
indicate the entry was updated successfully.
14 If the user chooses to drop
an advocate from an active trial
14.1 The system requests to update the entry
in the Advocates repository.
14.2 The database
updates the entry
14.3 The system displays a message to
indicate the entry was updated successfully.
15 The system displays the Patient
Advocates page.

UC1001: Manage Trial Candidate
Participating Actors: Patient Advocate
Description: Maintain information required to refer a subject for a clinical trial. A trial
candidate and information associated with that subject can be added, changed, displayed, or
deleted. Once all required information is completed, a request can be submitted
Preconditions:
1. User is authorized to perform read, create, update, and delete information about trial
candidates.
2. User has accessed the application logon page.
Postconditions: An entry for a trial candidate has been read, created, updated, or deleted.
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Main Success Scenario
Actor
1 The user requests to log into the
system.

System

Resource

2 The system requests user authorization
/ authentication.
3 Return authorization
/ authentication status.
4 The system displays the Trial
Candidates page showing a list of
processing options.
5 If the user chooses to add a
candidate
5.1 The system displays a form to collect
information.
5.2 The user enters the required
information and submits a request.
5.3 The system verifies that the form
fields contain valid data.
5.4 The system requests to create an
entry in the Candidates repository.
5.5 The database
creates an entry.
5.6 The system displays a message to
indicate the entry was created
successfully.
6 If the user chooses to review,
update, or delete
6.1 The system displays options to
process a single entry or multiple entries.
6.2. If the user chooses to process
from a list of candidates from the
repository
6.2.1 The system requests to retrieve all
entries in the Candidates repository
associated with the advocate.
6.2.2 The database
retrieves all entries.
6.2.3 The system displays the results,
sorted in alphabetical order by last name.
6.2.4 The user selects one of
candidates to process and submits
a request to refer or drop.
6.3 If the user chooses to process
a single entry
6.3.1 The system displays a form to enter
the name of the candidate.
6.3.2 The user updates the form
and submits a request to update or
delete.
6.3.3 The system verifies that the form
fields contain valid data.
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6.4 The system requests to retrieve the
entry in the Candidates repository for the
requested candidate.
6.4.1 The database
retrieves the entry.
6.4.2 The system displays the current
data for the candidate.
6.5 If the user chooses to change
information about a candidate
6.5.1 The user updates the form
and submits a request.
6.5.2 The system verifies that the form
fields contain valid data.
6.5.3 The system requests to update the
entry in the Candidates repository.
6.5.4 The database
updates the entry
6.5.5 The system displays a message to
indicate the entry was updated
successfully.
6.6 If the user chooses to delete a
candidate from the repository
6.6.1 If the user confirms delete
6.6.2 The system requests to delete the
entry from the Candidates repository.
6.6.3 The database
deletes the entry.
6.6.4 The system displays a message to
indicate the entry was deleted
successfully.
6.6.5 If the user cancels delete
7 The system displays the Trial
Candidates page.

UC1002: Request Subject Referral
Participating Actors: Patient Advocate
Description: Request to refer a subject to an active trial. Information can be added or changed.
Preconditions:
1. User is authorized to perform read, create, update, and delete participants.
2. User has accessed the application logon page.
Postconditions: Advocate has been added or dropped from a clinical trial.
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Main Success Scenario
Actor
1 The user requests to log into
the system.

System

Resource

2 The system requests user authorization /
authentication.
3 Return authorization
/ authentication status.
4 The system displays the Trial Candidates
page with options to process a single entry
or multiple entries.
5 If the user chooses to process
from a list of candidates from
the repository
5.1 The system requests to retrieve all
entries in the Candidates repository
associated with the advocate.
5.2 The database
retrieves all entries.
5.3 The system displays the results, sorted
in alphabetical order by last name.
5.4 The user selects one of
candidates to process and
submits the request.
6 If the user chooses to process
a single entry
6.1 The system displays a form to enter the
name of the candidate.
6.2 The user updates the form
and submits a request to
retrieve.
6.3 The system verifies that the form fields
contain valid data.
7 The system requests to retrieve the entry
in the Candidate repository for the
requested candidate.
8 The database
retrieves the entry.
9 The system requests to retrieve a list of
active trials from the Trials repository
associated with the advocate.
10 The database
retrieves the list.
11 The system displays the current data for
the candidate and processing options
12 If the user chooses to view
trial information
12.1 The system requests to retrieve trial
information from the Trials repository.
12.2 The database
retrieves the
information.
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12.3 The system displays trial information
and processing options.
13 The user chooses to refer the
candidate for the trial or to drop
the candidate.
13.1 The system requests to update the
entry in the Candidates repository.
13.2 The database
updates the entry.
13.3 The system displays a message to
indicate the entry was updated
successfully.
14 The system displays the Trial
Candidates page.

UC1003: Manage Referral Request
Participating Actors: Site Registrar
Description: Review trial candidate referrals and approves or rejects for registration.
Preconditions:
1. User is authorized to review trial candidate referrals.
2. User has accessed the application logon page.
Postconditions: A trial candidate has been reviewed, accepted, or rejected for a clinical trial.
Main Success Scenario
Actor
1 The user requests to log into
the system.

System

Resource

2 The system requests user authorization /
authentication.
3 Return authorization /
authentication status.
4 The system displays the Trial
Candidates page with options to process a
single entry or multiple entries.
5 If the user chooses to process
from a list of candidates from
the repository
5.1 The system requests to retrieve all
entries in the Candidates repository
associated with the advocate.
5.2 The database
retrieves all entries.
5.3 The system displays the results,
sorted in alphabetical order by last name.
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5.4 The user selects one of
candidates to process and
submits the request.
6 If the user chooses to process
a single entry
6.1 The system displays a form to enter
the name of the candidate.
6.2 The user updates the form
and submits a request to
retrieve.
6.3 The system verifies that the form
fields contain valid data.
7 The system requests to retrieve the
entry in the Candidate repository for the
requested candidate.
8 The database retrieves
the entry.
9 The system requests to retrieve a list of
active trials from the Trials repository
associated with the advocate.
10 The database
retrieves the list.
11 The system displays the current data
for the candidate and processing options
12 If the user chooses to view
trial information
12.1 The system requests to retrieve trial
information from the Trials repository.
12.2 The database
retrieves the information.
12.3 The system displays trial
information and processing options.
13 The user chooses to accept
the candidate for the trial or to
accept the candidate.
13.1 The system requests to add the
patient to the trial.
13.2 The Patient service
adds the candidate.
13.3 The system requests to register the
patient in the trial
13.4 The Registration
service registers the
candidate.
13.5 The system displays a message to
indicate the entry was updated
successfully.
14 The system displays the Trial
Candidates page.
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UC2001: Monitor Subject – Study Subject
Participating Actors: Study Subject
Description: Review trial data for the study subject and submit questions to researchers.
Preconditions:
1. User is authorized to the system.
2. User has accessed the application logon page.
Postconditions: Trial data has been viewed, a question has been submitted, or a response has
been viewed.
Main Success Scenario
Actor
1 The user requests to log into
the system.

System

Resource

2 The system requests user authorization
/ authentication.
3 Return authorization /
authentication status.
4 The system displays a list of
processing options.
5 If the user chooses to
retrieve data
5.1 The system requests to retrieve trial
data for the user from the Trial Data
database.
5.2 The database retrieves
the trial data.
5.3 The system displays the trial data.
6 If the user chooses to submit
a question
6.1 The system displays a form for the
question.
6.2 The user enters the
question on the form and
submits it.
6.3 The system requests the question to
be posted in the Communications
database.
6.4 The database creates an
entry.
6.5 The system displays a message
indicating the question has been posted.
7 If the user chooses to
retrieve communications
7.1 The system requests to retrieve all
communications for the user.
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7.2 The database retrieves
all communications.
7.3 The system displays
communications and a menu of options.
7.4 If the user chooses to view
a selected communication
7.4.1 The system displays the
communication in a pop-up window.
7.4.2 The user closes the
window.
8 The system displays the Trial
Monitoring page.

UC2002: Monitor Subject – Enrolling Physician
Participating Actors: Enrolling Physician
Description: Review trial data for the patients who are participating in a study and submit
questions to researchers.
Preconditions:
1. User is authorized to the system.
2. User has accessed the application logon page.
Postconditions: Trial data has been viewed, a question has been submitted, or a response has
been viewed.
Main Success Scenario
Actor
1 The user requests to log
into the system.

System

Resource

2 The system requests user authorization /
authentication.
3 Return authorization
/ authentication status.
4 The system displays the Trial Monitoring
page with options to process a single entry or
multiple entries.
5 If the user chooses to
process from a list of
patients from the repository
5.1 The system requests to retrieve all entries
in the Candidates repository that are registered
for one or more trials and are associated with
the enrolling physician.
5.2 The database
retrieves all entries.
5.3 The system displays the results, sorted in
alphabetical order by last name.
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5.4 The user selects one of
patients to process and
submits the request.
6 If the user chooses to
process a single entry
6.1 The system displays a form to enter the
name of the patient.
6.2 The user updates the
form and submits a request
to retrieve.
6.3 The system verifies that the form fields
contain valid data.
7 The system requests to retrieve the entry in
the Candidate repository for the requested
candidate.
8 The database
retrieves the entry.
9 The system requests to retrieve a list of trials
from the Trials repository associated with the
patient.
10 The database
retrieves the list.
11 The system displays the current trials for the
patient and processing options
12 If the user chooses to
retrieve trial data
12.1 The system requests to retrieve trial data
for the patient from the Trial Data database.
12.2 The database
retrieves the trial data.
12.3 The system displays the trial data.
13 If the user chooses to
submit a question
13.1 The system displays a form for the
question.
13.2 The user enters the
question on the form and
submits it.
13.3 The system requests the question to be
posted in the Communications database.
13.4 The database
creates an entry.
13.5 The system displays a message indicating
the question has been posted.
14 If the user chooses to
retrieve communications
14.1 The system requests to retrieve all
communications for the user.
14.2 The database
retrieves all
communications.
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14.3 The system displays communications and
a menu of options.
14.4 If the user chooses to
view a selected
communication
14.4.1 The system displays the communication
in a pop-up window.
14.4.2 The user closes the
window.
15 The system displays the Trial Monitoring
page.

UC2003: Monitor Trial Data
Participating Actors: Enrolling Physician, Community Member
Description: Review summary trial data and submit questions to researchers.
Preconditions:
1. User is authorized to the system.
2. User has accessed the application logon page.
Postconditions: Summary trial data has been viewed, a question has been submitted, or a
response has been viewed.
Main Success Scenario
Actor
1 The user requests to log into
the system.

System

Resource

2 The system requests user authorization /
authentication.
3 Return authorization /
authentication status.
4 The system displays a list of processing
options.
5 If the user chooses to
retrieve data
5.1 The system requests to retrieve trial
data from the Trial Data database for the
associated user.
5.2 The database retrieves
the trial data.
5.3 The system displays the trial data.
6 If the user chooses to
submit a question
6.1 The system displays a form for the
question.
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6.2 The user enters the
question on the form and
submits it.
6.3 The system requests the question to be
posted in the Communications database.
6.4 The database creates
an entry.
6.5 The system displays a message
indicating the question has been posted.
7 If the user chooses to
retrieve communications
7.1 The system requests to retrieve all
communications for the user.
7.2 The database retrieves
all communications.
7.3 The system displays communications
and a menu of options.
7.4 If the user chooses to
view a selected
communication
7.4.1 The system displays the
communication in a pop-up window.
7.4.2 The user closes the
window.
8 The system displays the Trial
Monitoring page.

UC2004: Obtain Trial Data
Participating Actors: Enrolling Physician, Community Member
Description: Reports for members of the community, including interim reports on trial subjects,
interim reports on the overall trial, and final reports on trial outcomes. The reports allow trial
subjects to monitor their progress and make decisions about their participation; they allow
enrolling physicians to monitor their patient’s progress; and they keep members of the
community engaged.
Preconditions:
1. User is authorized to the system.
2. Reports have been pre-defined.
Postconditions: The report has been provided.

UC3001: Disseminate Trial Results
Participating Actors: Community Outreach Coordinator
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Description: This process describes the steps for obtaining trial outcome reports and distributing
them to members of the community.
Preconditions:
1. User is authorized to the system.
Postconditions: A report has been distributed.
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Appendix I Petri Net for Monitor Subject Application

Figure 40 shows a Petri net representing the flow of the Monitor Subject application.
Annotations are noted in Table 36. This application is complex in that it requires
invocation of several internal and external web services. A Petri net can be used to
validate this part of the solution.

Figure 40. Petri net for Monitor Subject.

Table 36. Annotations for Monitor Subject.
Place /
Transition
P0
P1
P2
P3
P4
P5

Interpretation Description
User
Web Page
Data
User
Web Page
Service

Not logged in
Application logon page (web server is available)
List of authorized users
Logged in
Monitor Subject page
Connection to Confirm Patient Advocate Status
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P6
P7
P8
P9
P10
P11
P12
P13
P14
T0
T1
T2

Data
Service
Data
Service
Data
Service
Data
Service
Data
Task
Task
Task

T3

Task

T4

Task

T5

Task

T6

Task

T7
T8

Task
Task

T9
T10
T11
T12

Task
Task
Task
Task

Request to Register Patient Advocate
Connection to Register Patient Advocate
Patient Advocate Status
Connection to Confirm Subject Status
Request to Confirm Subject Status
Connection to Registration
Subject Status
Connection to Obtain Trial Data
Trial Data
Log in user
Display Monitor Subject page (home page)
Obtain connection to Confirm Patient Advocate Status service;
submit request to service
Obtain connection to Register Patient Advocate; submit request to
service
Release connection to Register Patient Advocate; return patient
advocate status
Release connection to Confirm Patient Advocate Status; return
patient advocate status
Obtain connection to Confirm Subject Status; submit request to
service
Obtain connection to Registration; submit request to service
Release connection to Confirm Subject Status; return subject
status
Release connection to Registration; return subject status
Obtain connection to Obtain Trial Data
Release connection to Obtain Trial Data; return data
Log out user
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Appendix J Glossary of Terms

caBIG

Cancer Biomedical Informatics Grid. This platform and
infrastructure is used by the National Cancer Institute to integrate
and ensure interoperability among various systems designed to
manage cancer research.

CDMS

Clinical Data Management System. This system is used by clinical
researchers to manage data associated with one or more clinical
trials.

COTS

Commercial Off-the-Shelf Software.

CRO

Contract Research Organization. This organization performs
research activities on behalf of a client.

CRUD

Create, Read, Update, Delete. This acronym is used to describe
basic functions typically associated with software data.

CTMS

Clinical Trial Management System. This system is used by
clinical researchers to manage the clinical trials process.

CTS

Clinical Trial Suite. This is a CTMS that is developed by the
National Cancer Institute.

Design Model

This is a document used during the Specification phase of the
RUP/SOMA methodology to model the high-level design of a web
service. Refer to Appendix E for more details about its content.

KPI

Key Performance Indicator. This is a metric that is used to
measure the performance of a process or tool.

NIH

National Institute of Health.

Petri net

This is a modeling notation that can be used to represent
asynchronous and concurrent processes.

RUP

Rational Unified Process. This is a software development process
that describes how requirements are transformed into software.

Service Model

This is a document that is used throughout all phases of the
RUP/SOMA methodology to model a web service. Refer to
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Appendix E for more details about its content.
SOA

Service-Oriented Architecture. This is an architectural style that
focuses on building discrete, reusable services.

SOMA

Service-Oriented Modeling and Architecture. This is a
methodology developed by IBM for defining and implementing an
SOA.

Type 1 dependency SOMA defines a Type 1 dependency as a functional dependency.
When Service A is composed of Service B and Service C, it has
Type 1 dependencies on both Service B and Service C.
Type 2 dependency SOMA defines a Type 2 dependency as a temporal dependency.
When Service A can only be invoked after Service B has been
executed, it has a Type 2 dependency on Service B.
UML

Unified Modeling Language. This is a visual modeling language
that can be used to describe software systems.
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